<SEC-DOCUMENT>0001104659-20-091529.txt : 20200806
<SEC-HEADER>0001104659-20-091529.hdr.sgml : 20200806
<ACCEPTANCE-DATETIME>20200806171659
ACCESSION NUMBER:		0001104659-20-091529
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20200806
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200806
DATE AS OF CHANGE:		20200806

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SELECTA BIOSCIENCES INC
		CENTRAL INDEX KEY:			0001453687
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37798
		FILM NUMBER:		201082777

	BUSINESS ADDRESS:	
		STREET 1:		480 ARSENAL WAY
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		617-923-1400

	MAIL ADDRESS:	
		STREET 1:		480 ARSENAL WAY
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2026355-3_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:selb="http://selectabio.com/20200806">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_03A_selb_selectabio.com_20200806 -->
<!-- Field: Set; Name: xdx; ID: xdx_046_20200806_20200806 -->
<!-- Field: Set; Name: xdx; ID: xdx_05B_edei%2D%2DEntityCentralIndexKey_0001453687 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
  <ix:hidden>
    <ix:nonNumeric contextRef="From2020-08-06to2020-08-06" name="dei:EntityCentralIndexKey">0001453687</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-08-06to2020-08-06" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    </ix:hidden>
  <ix:references>
    <link:schemaRef xlink:href="selb-20200806.xsd" xlink:type="simple" />
    </ix:references>
  <ix:resources>
    <xbrli:context id="From2020-08-06to2020-08-06">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-08-06</xbrli:startDate>
        <xbrli:endDate>2020-08-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    </ix:resources>
  </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES<br />
SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_906_edei--DocumentType_c20200806__20200806_zEiVaAMz4Fa9"><ix:nonNumeric contextRef="From2020-08-06to2020-08-06" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d) of</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of report (Date of earliest event
reported): <span id="xdx_90E_edei--DocumentPeriodEndDate_c20200806__20200806_zsNTtXIwvAGf"><ix:nonNumeric contextRef="From2020-08-06to2020-08-06" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">August 6, 2020</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_909_edei--EntityRegistrantName_c20200806__20200806_z2I35PbgzTZb"><ix:nonNumeric contextRef="From2020-08-06to2020-08-06" name="dei:EntityRegistrantName">SELECTA BIOSCIENCES, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
<td style="width: 30%; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_908_edei--EntityIncorporationStateCountryCode_c20200806__20200806_zOV4vVGxYnDc"><ix:nonNumeric contextRef="From2020-08-06to2020-08-06" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
<td style="width: 40%; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90E_edei--EntityFileNumber_c20200806__20200806_zoC96yzgkPL4"><ix:nonNumeric contextRef="From2020-08-06to2020-08-06" name="dei:EntityFileNumber">001-37798</ix:nonNumeric></span></b></span></td>
<td style="width: 30%; font-size: 10pt; text-align: center"><b><span id="xdx_909_edei--EntityTaxIdentificationNumber_c20200806__20200806_zRirqMqoJvTa"><ix:nonNumeric contextRef="From2020-08-06to2020-08-06" name="dei:EntityTaxIdentificationNumber">26-1622110</ix:nonNumeric></span></b></td></tr>
<tr style="vertical-align: top">
<td style="text-align: center">(State or other jurisdiction of <br />
incorporation or organization)</td>
<td style="text-align: center">(Commission <br />
File Number) &#160;</td>
<td style="text-align: center">(I.R.S. Employer <br />
Identification No.)</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b><span id="xdx_904_edei--EntityAddressAddressLine1_c20200806__20200806_z62JnhG3TaL8"><ix:nonNumeric contextRef="From2020-08-06to2020-08-06" name="dei:EntityAddressAddressLine1">65 Grove Street</ix:nonNumeric></span></b> <b><span id="xdx_90A_edei--EntityAddressCityOrTown_c20200806__20200806_zOosIcRn61ja"><ix:nonNumeric contextRef="From2020-08-06to2020-08-06" name="dei:EntityAddressCityOrTown">Watertown</ix:nonNumeric></span>, <span id="xdx_902_edei--EntityAddressStateOrProvince_c20200806__20200806_zsiWPmKlx245"><ix:nonNumeric contextRef="From2020-08-06to2020-08-06" name="dei:EntityAddressStateOrProvince">MA</ix:nonNumeric></span> <span id="xdx_90C_edei--EntityAddressPostalZipCode_c20200806__20200806_zOdnQgSlT1Oe"><ix:nonNumeric contextRef="From2020-08-06to2020-08-06" name="dei:EntityAddressPostalZipCode">02472</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">(Address of principal executive offices) (Zip Code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>(<span id="xdx_907_edei--CityAreaCode_c20200806__20200806_zBL1XjgqDLU2"><ix:nonNumeric contextRef="From2020-08-06to2020-08-06" name="dei:CityAreaCode">617</ix:nonNumeric></span>) <span id="xdx_90C_edei--LocalPhoneNumber_c20200806__20200806_zspY1J1Pz8wk"><ix:nonNumeric contextRef="From2020-08-06to2020-08-06" name="dei:LocalPhoneNumber">923-1400</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b></b> (Registrant&#8217;s telephone number, include area code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>N/A</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b></b> (Former Name or Former Address, if Changed Since Last Report)</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35pt"><b></b></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35pt"><span style="font-family: Wingdings"><span id="xdx_902_edei--WrittenCommunications_c20200806__20200806_zuBIbUSvKlr4"><ix:nonNumeric contextRef="From2020-08-06to2020-08-06" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35pt"><span style="font-family: Wingdings"><span id="xdx_90D_edei--SolicitingMaterial_c20200806__20200806_zT9d3oqyR7gi"><ix:nonNumeric contextRef="From2020-08-06to2020-08-06" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a&#45;12)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35pt"><span style="font-family: Wingdings"><span id="xdx_906_edei--PreCommencementTenderOffer_c20200806__20200806_zlGhBAhDJUvk"><ix:nonNumeric contextRef="From2020-08-06to2020-08-06" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35pt"><span style="font-family: Wingdings"><span id="xdx_907_edei--PreCommencementIssuerTenderOffer_c20200806__20200806_zHkL5BWAmeZ4"><ix:nonNumeric contextRef="From2020-08-06to2020-08-06" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">S<span style="font-size: 10pt">ecurities
registered pursuant to Section 12(b) of the Act</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="border-bottom: Black 1pt solid; padding-top: 1pt; text-align: center; width: 38%; padding-bottom: 1pt"><b>Title of each class</b></td>
<td style="padding-top: 1pt; text-align: center; width: 2%; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; padding-top: 1pt; width: 20%; font-size: 10pt; text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt"><b>Trading Symbol(s)</b></span></td>
<td style="padding-top: 1pt; text-align: center; width: 2%; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; padding-top: 1pt; text-align: center; width: 38%; padding-bottom: 1pt"><b>Name of each exchange on which registered</b></td></tr>
<tr style="vertical-align: top">
<td style="padding-top: 1pt; font-size: 10pt; text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt"><span id="xdx_907_edei--Security12bTitle_c20200806__20200806_zVsULSDaBoR"><ix:nonNumeric contextRef="From2020-08-06to2020-08-06" name="dei:Security12bTitle">Common stock, par value $0.001 per share</ix:nonNumeric></span></span></td>
<td style="padding-top: 1pt; text-align: center; padding-bottom: 1pt">&#160;</td>
<td style="padding-top: 1pt; font-size: 10pt; text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt"><span id="xdx_90C_edei--TradingSymbol_c20200806__20200806_zqdEkmugI4a4"><ix:nonNumeric contextRef="From2020-08-06to2020-08-06" name="dei:TradingSymbol">SELB</ix:nonNumeric></span></span></td>
<td style="padding-top: 1pt; text-align: center; padding-bottom: 1pt">&#160;</td>
<td style="padding-top: 1pt; font-size: 10pt; text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt"><span id="xdx_90A_edei--SecurityExchangeName_c20200806__20200806_z5kSwUa6Sa42"><ix:nonNumeric contextRef="From2020-08-06to2020-08-06" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The Nasdaq Global Market</ix:nonNumeric></span></span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-size: 10pt">Emerging growth company
</span><span style="font-family: Wingdings"><span id="xdx_905_edei--EntityEmergingGrowthCompany_c20200806__20200806_zdmJJMa4rYCc"><ix:nonNumeric contextRef="From2020-08-06to2020-08-06" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany">&#120;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-size: 10pt">If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_90F_edei--EntityExTransitionPeriod_c20200806__20200806_zYeLccUdADha"><ix:nonNumeric contextRef="From2020-08-06to2020-08-06" format="ixt:booleantrue" name="dei:EntityExTransitionPeriod">&#120;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 1.01. Entry into a Material Definitive Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 6, 2020, Selecta Biosciences, Inc. (the &#8220;Company&#8221;)
entered into an Open Market Sale Agreement<span style="font-size: 10pt"><sup>SM</sup></span> (the &#8220;Sale Agreement&#8221;)
with Jefferies LLC (&#8220;Jefferies&#8221;) to sell shares of the Company&#8217;s common stock, par value $0.0001 per share (the
&#8220;Common Stock&#8221;), with aggregate gross sales proceeds of up to $50,000,000, from time to time, through an &#8220;at
the market&#8221; equity offering program under which Jefferies will act as sales agent. The shares of Common Stock sold pursuant
to the Sale Agreement will be issued pursuant to the Company&#8217;s shelf registration statement on Form S-3 (File No. 333-241692)
and related prospectus supplement, each filed on August 6, 2020 with the Securities and Exchange Commission.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the Sale Agreement, the Company will set the parameters
for the sale of shares, including the number of shares to be issued, the time period during which sales are requested to be made,
limitations on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be
made. Subject to the terms and conditions of the Sale Agreement, Jefferies may sell the shares by methods deemed to be an &#8220;at
the market offering&#8221; as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the &#8220;Securities
Act&#8221;), in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing
market prices and/or any other method permitted by law. If the Company and Jefferies so agree, Jefferies may act as principal in
connection with the sale of shares under the Sale Agreement. The Company will pay Jefferies a commission of up to 3.0% of the gross
sales proceeds of any shares of Common Stock sold through Jefferies under the Sale Agreement, and also has provided Jefferies with
customary indemnification rights. The offering of shares of Common Stock pursuant to the Sales Agreement will terminate upon the
earlier of (i) the sale of all shares of Common Stock subject to the Sales Agreement and (ii) the termination of the Sales Agreement
as permitted therein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The foregoing description of the material terms of the Sale
Agreement is qualified in its entirety by reference to the full agreement, a copy of which is filed as Exhibit 1.1 to this Current
Report on Form 8-K and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Current Report on Form 8-K shall not constitute an offer
to sell or the solicitation of any offer to buy the securities discussed herein, nor shall there be any offer, solicitation or
sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such state.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9.01. Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 49pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 49pt">(d)&#160;Exhibits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; padding-top: 1pt; width: 10%">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Exhibit</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>No.</b></p></td>
    <td style="padding-top: 1pt; width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; padding-top: 1pt; width: 87%; text-align: center"><span style="font-size: 10pt"><b>Description</b></span></td></tr>
<tr>
    <td style="padding-top: 1pt; text-align: center; padding-bottom: 1pt"><a href="tm2026355d3_ex1-1.htm" style="-sec-extract: exhibit">1.1#</a></td>
    <td style="padding-top: 1pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-top: 1pt; padding-bottom: 1pt"><a href="tm2026355d3_ex1-1.htm" style="-sec-extract: exhibit">Open Market Sale Agreement, dated as of August 6, 2020, by and between Selecta Biosciences, Inc. and Jefferies LLC.</a></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"># The representations and warranties contained in this agreement were made only for purposes of the transactions contemplated by the agreement
as of specific dates and may have been qualified by certain disclosures between the parties and a contractual standard of materiality
different from those generally applicable under securities laws, among other limitations. The representations and warranties were made
for purposes of allocating contractual risk between the parties to the agreement and should not be relied upon as a disclosure of factual
information relating to the Company, Jefferies or the transactions described in this Current Report on Form 8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">SELECTA BIOSCIENCES,&#160;INC.</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 50%">Date: August 6, 2020</td>
    <td style="width: 3%">By:&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 47%">/s/ Carsten Brunn, Ph.D.</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>Carsten Brunn, Ph.D.</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>President and Chief Executive Officer</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>



<p style="margin: 0"></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KwjAMhZ9g7xB6LVqHf+xOh4o4RcYQb4uLUtyakXZTH8m3tNsQQyAk53w5QgzElja6QIbLKk0gw7IqlENI8YaM5oreEe/2EfiZ4l1bx8q4bv2BMXkGPTMdTpS/d85GW8wjkIuRnI1CCXIeTRewPIig1WMyN52jcVoVoEwOJ6aKNTrF7/5Dpl5kqHx3SWdkq8lEMB7KXv5AKMchHKlRT+KHhSSJRTDoKhBbprpqY2rrqIR1gaXPsj367+AL25RJFQ== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>tm2026355d3_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 1.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>OPEN
MARKET SALE AGREEMENT</U></B></FONT><SUP>SM</SUP></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-weight: normal">August
6, 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in 0pt 0; text-indent: 0in">JEFFERIES LLC<BR>
520 Madison Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">New York, New York 10022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selecta
Biosciences, Inc., a Delaware corporation (the &#8220;<B>Company</B>&#8221;), proposes, subject to the terms and conditions stated
herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the &#8220;<B>Agent</B>&#8221;),
shares of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;<B>Common Shares</B>&#8221;), having an aggregate
offering price of up to $50,000,000 on the terms set forth in this agreement (this &#8220;<B>Agreement</B>&#8221;)</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
1.</B></FONT> DEFINITIONS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Certain Definitions</U>. For purposes of this Agreement, capitalized terms used herein and not otherwise defined shall
have the following respective meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<B>Affiliate</B>&#8221;
of a Person means another Person that directly or indirectly, through one or more intermediaries, controls, is controlled by,
or is under common control with, such first-mentioned Person. The term &#8220;<B>control</B>&#8221; (including the terms &#8220;<B>controlling</B>,&#8221;
&#8220;<B>controlled by</B>&#8221; and &#8220;<B>under common control with</B>&#8221;) means the possession, direct or indirect,
of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting
securities, by contract or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<B>Agency
Period</B>&#8221; means the period commencing on the date of this Agreement and expiring on the earliest to occur of (x) the date
on which the Agent shall have placed the Maximum Program Amount pursuant to this Agreement, (y) the date this Agreement is terminated
pursuant to </FONT><U>Section 7</U> and (z) the third anniversary <FONT STYLE="text-underline-style: double">of the </FONT>date
of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<B>Commission</B>&#8221;
means the U.S. Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<B>Exchange
Act</B>&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<B>Floor Price</B>&#8221;
means the minimum price set by the Company in the Issuance Notice below which the Agent shall not sell Shares during the applicable
period set forth in the Issuance Notice, which may be adjusted by the Company at any time during the period set forth in the Issuance
Notice by delivering written notice of such change to the Agent and which in no event shall be less than $1.00 without the prior
written consent of the Agent, which may be withheld in the Agent&#8217;s sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>SM</SUP></FONT>
&#8220;Open Market Sale Agreement&#8221; is a service mark of Jefferies LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<B>Issuance
Amount</B>&#8221; means the aggregate Sales Price of the Shares to be sold by the Agent pursuant to any Issuance Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<B>Issuance
Notice</B>&#8221; means a written notice delivered to the Agent by the Company in accordance with this Agreement in the form attached
hereto as <U>Exhibit A</U> that is executed by its Chief Executive Officer<FONT STYLE="text-underline-style: double">, President
or Chief Financial Officer</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<B>Issuance
Notice Date</B>&#8221; means any Trading Day during the Agency Period that an Issuance Notice is <FONT STYLE="text-underline-style: double">delivered
</FONT>pursuant to </FONT><U>Section 3(b)(i)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<B>Issuance
Price</B>&#8221; means <FONT STYLE="text-underline-style: double">the Sales Price less the Selling Commission</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<B>Maximum
Program Amount</B>&#8221; means Common Shares with an aggregate Sales Price of the lesser of (a) the number or dollar amount of
Common Shares registered under the effective Registration Statement (defined below) pursuant to which the offering is being made,
(b) the number of authorized but unissued Common Shares (less Common Shares issuable upon exercise, conversion or exchange of
any outstanding securities of the Company or otherwise reserved from the Company&#8217;s authorized capital stock), (c) the number
or dollar amount of Common Shares permitted to be sold under Form S-3 (including General Instruction I.B.6 thereof, if applicable),
or (d) the number or dollar amount of Common Shares for which the Company has filed a Prospectus (defined below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<B>Person</B>&#8221;
means an individual or a corporation, partnership, limited liability company, trust, incorporated or unincorporated association,
joint venture, joint stock company, governmental authority or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<B>Principal
Market</B>&#8221; means the Nasdaq Global Market or such other national securities exchange on which the Common Shares, including
any Shares, are then listed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<B>Sales Price</B>&#8221;
means the actual sale execution price of each Share placed by the Agent pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<B>Securities
Act</B>&#8221; means the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<B>Selling
Commission</B>&#8221; means up to three percent (3.0%) of the gross proceeds from the sale of any Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-underline-style: double">&#8220;<B>Settlement
Date</B>&#8221; </FONT>means the second business day following each Trading Day during the period set forth in the Issuance Notice
on which Shares are sold pursuant to this Agreement, when the Company shall deliver to the Agent the amount of Shares sold on
such Trading Day and the Agent shall deliver to the Company the Issuance Price received on such sales<FONT STYLE="text-underline-style: double; color: blue">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<B>Shares</B>&#8221;
shall mean the Common Shares issued or issuable pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<B>Trading Day</B>&#8221;
means any day on which the Principal Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Section 2. REPRESENTATIONS AND
WARRANTIES OF THE COMPANY</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company represents
and warrants to, and agrees with, the Agent that as of (1) the date of this Agreement, (2) each Issuance Notice Date, (3) each
Settlement Date, (4) each Triggering Event Date with respect to which the Company is obligated to deliver a certificate pursuant
to <U>Section 4(o)</U> and (5) each Time of Sale (each of the times referenced above is referred to herein as a &#8220;<B>Representation
Date</B>&#8221;), except as may be disclosed in the Time of Sale Information (including the Prospectus and any documents incorporated
by reference therein and any supplements thereto) on or before a Representation Date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Registration Statement</U>. The Company has prepared and filed or will prepare and file with the Commission a shelf registration
statement on Form&nbsp;S-3&nbsp;(or a successor registration statement on such form pertaining to the Shares to be sold pursuant
to this Agreement) that contains a base prospectus relating to the issuance and sale of Shares under this Agreement (the &#8220;<B>Base
Prospectus</B>&#8221;). Such registration statement registers the issuance and sale by the Company of the Shares under the Securities
Act. Such registration statement, including any information deemed to be a part thereof pursuant to Rule 430B under the Securities
Act, including all financial statements, exhibits and schedules thereto and all documents incorporated or deemed to be incorporated
therein by reference pursuant to Item 12 of Form S-3 under the Securities Act as from time to time amended or supplemented, is
herein referred to as the &#8220;<B>Registration Statement</B>,&#8221; and the Base Prospectus, together with any prospectus supplement
filed with the Commission pursuant to Rule 424(b) under the Securities Act relating to a particular issuance of the Shares, including
all documents incorporated or deemed to be incorporated therein by reference pursuant to Item 12 of Form S-3 under the Securities
Act, in each case, as from time to time amended or supplemented, is referred to herein as the &#8220;<B>Prospectus</B>,&#8221;
except that if any revised prospectus is provided to the Agent by the Company for use in connection with the offering of the Shares
that is not required to be filed by the Company pursuant to Rule 424(b) under the Securities Act, the term &#8220;<B>Prospectus</B>&#8221;
shall refer to such revised prospectus from and after the time it is first provided to the Agent for such use. The Registration
Statement at the time it originally became effective is herein called the &#8220;<B>Original Registration Statement</B>.&#8221;
As used in this Agreement, the terms &#8220;amendment&#8221; or &#8220;supplement&#8221; when applied to the Registration Statement
or the Prospectus shall be deemed to include the filing by the Company with the Commission of any document under the Exchange Act
after the date hereof that is or is deemed to be incorporated therein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All references in this
Agreement to financial statements and schedules and other information that is &#8220;contained,&#8221; &#8220;included&#8221; or
&#8220;stated&#8221; in the Registration Statement or the Prospectus (and all other references of like import) shall be deemed
to mean and include all such financial statements and schedules and other information that is or is deemed to be incorporated by
reference in or otherwise deemed under the Securities Act to be a part of or included in the Registration Statement or the Prospectus,
as the case may be, as of any specified date; and all references in this Agreement to amendments or supplements to the Registration
Statement or the Prospectus shall be deemed to mean and include, without limitation, the filing of any document under the Exchange
Act which is or is deemed to be incorporated by reference in or otherwise deemed under the Securities Act to be a part of or included
in the Registration Statement or the Prospectus, as the case may be, as of any specified date. The Company&#8217;s obligations
under this Agreement to furnish, provide, deliver or make available (and all other references of like import) copies of any report
or statement shall be deemed satisfied if the same is filed with the Commission through IDEA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the time the Registration Statement was or will be originally declared effective, the Company met or will meet the then-applicable
requirements for use of Form&nbsp;S-3 under the Securities Act.</FONT> During the Agency Period, each time the Company has filed
or files an annual report on Form 10-K the Company will meet the then-applicable requirements for use of Form S-3 under the Securities
Act, including, but not limited to, General Instruction I.B.1 thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Compliance with Registration Requirements</U>. The Original Registration Statement has been and any Rule&nbsp;462(b)
Registration Statement will have been or will be declared effective by the Commission under the Securities Act. The Company has
complied or will comply to the Commission&#8217;s satisfaction with all requests of the Commission for additional or supplemental
information with respect to the Registration Statement. No stop order suspending the effectiveness of the Registration Statement
or any Rule&nbsp;462(b) Registration Statement is in effect and no proceedings for such purpose have been instituted or are pending
or, to the knowledge of the Company, are contemplated or threatened by the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Prospectus when filed complied in all material respects with the Securities Act and, if filed by electronic transmission through
its Electronic Data Gathering, Analysis and Retrieval system (&#8220;<B>EDGAR</B>&#8221;) (except as may be permitted by Regulation&nbsp;S-T
under the Securities Act), was identical to the copy thereof delivered to the Agent for use in connection with the issuance and
sale of the Shares. Each of the Registration Statement, any Rule&nbsp;462(b) Registration Statement and any post-effective amendment
thereto, at the time it became effective and at each Representation Date, complied and will comply, as the case may be, in all
material respects with the Securities Act and did not and will not, as the case may be, contain any untrue statement of a material
fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading
(except that the foregoing shall not apply to those parts of the Registration Statement that constitute the Statement of Eligibility
(Form T-1) under the Trust Indenture Act of 1939). As of the date of this Agreement, the Prospectus and any Free Writing Prospectus
considered together do not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements therein, in the light of the circumstances under which they were made, not misleading. The Prospectus as of its date
and at each Representation Date, does not and will not, as the case may be, contain any untrue statement of a material fact or
omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading. The representations and warranties set forth in the three immediately preceding sentences do not
apply to statements in or omissions from the Registration Statement, any Rule&nbsp;462(b) Registration Statement or any post-effective
amendment thereto, or the Prospectus or any Free Writing Prospectus, or any amendments or supplements thereto, made in reliance
upon and in conformity with information relating to the Agent furnished to the Company in writing by the Agent expressly for use
therein, it being understood and agreed that the only such information furnished by the Agent to the Company consists of the information
described in </FONT><U>Section 6</U> below. The Registration Statement and the offer and sale of the Shares as contemplated hereby
meet the requirements of Rule 415 under the Securities Act and comply in all material respects with said Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: blue">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: blue"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: blue">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Ineligible
Issuer Status</U>. The Company is not an &#8220;ineligible issuer&#8221; in connection with the offering of the Shares
pursuant to Rules 164, 405 and 433 under the Securities Act. Any Free Writing Prospectus that the Company is required to file
pursuant to Rule 433(d) under the Securities Act has been, or will be, filed with the Commission in accordance with the
requirements of the Securities Act. Each Free Writing Prospectus that the Company has filed, or is required to file, pursuant
to Rule 433(d) under the Securities Act or that was prepared by or behalf of or used or referred to by the Company complies
or will comply, as the case may be, in all material respects with the requirements of Rule 433 under the Securities Act,
including timely filing with the Commission or retention where required and legending pursuant to Rule 433 under the
Securities Act, and each such Free Writing Prospectus, as of its issue date and at all subsequent times through the
completion of the issuance and sale of the Shares did not, does not and will not include any information that conflicted,
conflicts with or will conflict with the information contained in the Registration Statement or the Prospectus, as then
amended and supplemented. Except for the Free Writing Prospectuses, if any, and electronic road shows related to the offering
of Shares, if any, in each case, furnished to you before first use, the Company has not prepared, used or referred to, and
will not, without your prior consent, prepare, use or refer to, any Free Writing Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Incorporated Documents</U>. The documents incorporated or deemed to be incorporated by reference in the Registration
Statement and the Prospectus, at the time they were filed with the Commission, complied in all material respects with the requirements
of the Exchange Act, as applicable, and, when read together with the other information in the Prospectus, do not contain an untrue
statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements
therein, in light of the circumstances under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Exchange Act Compliance</U>. The documents incorporated or deemed to be incorporated by reference in the Prospectus,
at the time they were or hereafter are filed with the Commission or became effective under the Exchange Act, as the case may be,
and any Free Writing Prospectus or amendment or supplement related thereto complied or will comply, at the time of such filing
or effectiveness, in all material respects with the requirements of the Exchange Act, and, when read together with the other information
in the Prospectus, at the time the Registration Statement and any amendments thereto become effective and at each Representation
Date, will not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or
necessary to make the fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances
under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>EGC
Status</U>. The Company qualifies as an emerging growth company, as defined in Section 2(a)(19) of the Securities Act,
until no later than December 31, 2021.<SUP></SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>The Agreement</U>. This Agreement has been duly authorized, executed and delivered by, and is a valid and binding agreement
of, the Company, enforceable in accordance with its terms, except as rights to indemnification hereunder may be limited by applicable
law and except as the enforcement hereof may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar
laws relating to or affecting the rights and remedies of creditors or by general equitable principles.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Capitalization</U>. The Company has an authorized and outstanding capitalization as set forth in the sections of the
Registration Statement and the Prospectus entitled &#8220;Capitalization&#8221; and &#8220;Description of Capital Stock&#8221;
(subject to the issuance of Common Shares upon exercise of stock options and warrants disclosed as outstanding in the Registration
Statement and the Prospectus and the grant of options under existing stock option plans described in the Registration Statement
and the Prospectus); all of the issued and outstanding shares of capital stock of the Company, including the Common Shares, have
been duly authorized and validly issued and are fully paid and non-assessable, have been issued in compliance with all applicable
securities laws and were not issued in violation of any preemptive right, resale right, right of first refusal or similar right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Good Standing of Company</U>. The Company has been duly incorporated and is validly existing as a corporation in good
standing under the laws of the State of Delaware, with full corporate power and authority to own, lease and operate its properties
and conduct its business as described in the Registration Statement and the Prospectus, and to execute and deliver this Agreement
and to issue, sell and deliver the Shares as contemplated herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Foreign Qualification of Company</U>. The Company is duly qualified to do business as a foreign corporation and is in
good standing in each jurisdiction where the ownership or leasing of its properties or the conduct of its business requires such
qualification, except where the failure to be so qualified and in good standing would not, individually or in the aggregate, either
(i) have a material adverse effect on the business, properties, financial condition, results of operations or prospects related
thereto of the Company and the Subsidiaries taken as a whole, (ii) prevent or materially interfere with the consummation of the
transactions contemplated hereby or (iii) result in the delisting of the Common Shares from the Nasdaq Global Market (the occurrence
of any such effect or any such prevention or interference or any such result described in the foregoing clauses (i), (ii) or (iii)
being herein referred to as a &#8220;<B>Material Adverse Effect</B>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Good
Standing and Foreign Qualification of Subsidiaries</U>. The Company has no subsidiaries (as defined under the Securities Act)
other than the subsidiaries most recently disclosed in its filings available on EDGAR (collectively, the
&#8220;<B>Subsidiaries</B>&#8221;)<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP></SUP></FONT>; the Company
owns all of the issued and outstanding membership interests or capital stock of each of the Subsidiaries; other than the
membership interests or capital stock of the Subsidiaries, the Company does not own, directly or indirectly, any shares of
stock or any other equity interests or long-term debt securities of any corporation, firm, partnership, joint venture,
association or other entity; complete and correct copies of the charters and the bylaws or similar governing documents of the
Company and each Subsidiary and all amendments thereto have been delivered to you (including by being made available to you
through EDGAR), and no changes therein will be made on or after the date hereof through and including the time of any time of
purchase; each Subsidiary has been duly incorporated and is validly existing as a corporation in good standing under the laws
of the jurisdiction of its incorporation, with full limited liability company or corporate power and authority to own, lease
and operate its properties and to conduct its business as described in the Registration Statement and the Prospectus; each
Subsidiary is duly qualified to do business as a foreign limited liability company or corporation and is in good standing in
each jurisdiction where the ownership or leasing of its properties or the conduct of its business requires such
qualification, except where the failure to be so qualified and in good standing would not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect; all of the outstanding membership interests or shares of capital
stock of each of the Subsidiaries have been duly authorized and validly issued, are fully paid and non-assessable, have been
issued in compliance with all applicable securities laws, were not issued in violation of any preemptive right, resale right,
right of first refusal or similar right and are owned by the Company subject to no security interest, other encumbrance or
adverse claims; no options, warrants or other rights to purchase, agreements or other obligations to issue or other rights to
convert any obligation into shares of capital stock or ownership interests in the Subsidiaries are outstanding; and each
&#8220;significant subsidiary&#8221; of the Company, as that term is defined in Rule 1-02(w) of Regulation S-X under the
Securities Act, is listed in Exhibit 21.1 to the Company&#8217;s most recent Annual Report on Form 10-K (or otherwise in a
subsequent filing available on EDGAR).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Authorization of the Shares</U>. The Shares have been duly and validly authorized and, when issued and delivered against
payment therefor as provided herein, will be duly and validly issued, fully paid and non-assessable and free of statutory and contractual
preemptive rights, resale rights, rights of first refusal and similar rights, except for any such rights that have been waived;
the Shares, when issued and delivered against payment therefor as provided herein, will be free of any restriction upon the voting
or transfer thereof pursuant to the Delaware General Corporation Law or the Company&#8217;s charter and bylaws, each as amended
to date and in the form filed as an exhibit to the Registration Statement, and any agreement or other instrument to which the Company
is a party, except for any such rights that have been waived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Description of Capital Stock</U>. The capital stock of the Company, including the Shares, conforms in all material respects
to each description thereof, if any, contained or incorporated by reference in the Registration Statement and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Non-Contravention</U>. Neither the Company nor any of the Subsidiaries is in breach or violation of or in default under
(nor has any event occurred which, with notice, lapse of time or both, would reasonably be expected to result in any breach or
violation of, constitute a default under or give the holder of any indebtedness (or a person acting on such holder&#8217;s behalf)
the right to require the repurchase, redemption or repayment of all or a part of such indebtedness under) (A) its charter or bylaws
or similar governing documents, or (B) any indenture, mortgage, deed of trust, bank loan or credit agreement or other evidence
of indebtedness, or any material license, lease, contract or other agreement or instrument to which it is a party or by which
it or any of its properties may be bound or affected, or (C) any U.S. or Russian federal, state, local or foreign law, regulation
or rule, or (D) any rule or regulation of any self-regulatory organization or other non-governmental regulatory authority having
jurisdiction over the Company or the Subsidiaries (including, without limitation, the rules and regulations of the Nasdaq Global
Market), or (E) any decree, judgment or order applicable to it or any of its properties, except in the case of the foregoing clauses
(B), (C), (D) and (E), for any such breaches, violations, defaults or events that would not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect; The execution, delivery and performance of this Agreement, the issuance
and sale of the Shares and the consummation of the transactions contemplated hereby will not conflict with, result in any breach
or violation of or constitute a default under (nor constitute any event which, with notice, lapse of time or both, would reasonably
be expected to result in any breach or violation of, constitute a default under or give the holder of any indebtedness (or a person
acting on such holder&#8217;s behalf) the right to require the repurchase, redemption or repayment of all or a part of such indebtedness
under) (or result in the creation or imposition of a lien, charge or encumbrance on any property or assets of the Company or any
Subsidiary pursuant to) (A) the charter or bylaws of the Company or similar organizational documents of any of the Subsidiaries,
or (B) any indenture, mortgage, deed of trust, bank loan or credit agreement or other evidence of indebtedness, or any license,
lease, contract or other agreement or instrument to which the Company or any of the Subsidiaries is a party or by which any of
them or any of their respective properties is subject, or (C) any U.S. or Russian federal, state, local or foreign law, regulation
or rule, or (D) any rule or regulation of any self-regulatory organization or other non-governmental regulatory authority having
jurisdiction over the Company or the Shares (including, without limitation, the rules and regulations of the Nasdaq Global Market),
or (E) any decree, judgment or order applicable to the Company or any of the Subsidiaries or any of their respective properties,
except in the case of the foregoing clauses (B), (C), (D) and (E), for any such breaches, violations, defaults, repurchases, redemptions,
repayments or events that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Further Authorizations or Approvals Required</U>. No approval, authorization, consent or order of or filing with any
federal, state, local or foreign governmental or regulatory commission, board, body, authority or agency, or of or with any self-regulatory
organization or other non-governmental regulatory authority (including, without limitation, the Nasdaq Global Market), or approval
of the stockholders of the Company is required in connection with the issuance and sale of the Shares or the consummation by the
Company of the transactions contemplated hereby, other than (i) the registration of the Shares under the Securities Act , which
has been effected (or, with respect to any registration statement to be filed hereunder pursuant to Rule 462(b) under the Act,
will be effected in accordance herewith), (ii) any necessary qualification under the securities or blue sky laws of the various
jurisdictions in which the Shares are being offered by the Agent, (iii) under the Conduct Rules of Financial Industry Regulatory
Authority, Inc. (&#8220;<B>FINRA</B>&#8221;), (iv) any listing applications and related consents or any notices required by the
Nasdaq Global Market in the ordinary course of the offering of the Shares or (v) filings with the Commission pursuant to Rule 424(b)
under the Securities Act, except as have already been made, obtained or waived or where the failure to obtain any such approval,
authorization, consent, order or filing would not impair the ability of the Company to issue and sell the Shares or to consummate
the transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>No
Preemptive or Similar Rights</U>. Except as described in the Registration Statement and the Prospectus or as otherwise have
been waived (i) no person has the right, contractual or otherwise, to cause the Company to issue or sell to it any Common
Shares or shares of any other capital stock or other equity interests of the Company, (ii) no person has any preemptive
rights, resale rights, rights of first refusal or other rights to purchase any Common Shares or shares of any other capital
stock of or other equity interests in the Company and (iii) no person has the right to act as an underwriter or as a
financial advisor to the Company in connection with the offer and sale of the Shares; no person has the right, contractual or
otherwise, to cause the Company to register under the Securities Act any Common Shares or shares of any other capital stock
of or other equity interests in the Company or to include any such shares or interests in the Registration Statement or the
offering contemplated thereby other than those that have been otherwise waived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Split-Segment; Name: a1 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Regulatory Compliance</U>. Except for licenses, authorizations, consents and approvals required to be obtained from the
Food and Drug Administration of the U.S. Department of Health and Human Services, each of the Company and the Subsidiaries has
obtained all necessary licenses, authorizations, consents and approvals from all applicable authorities, in each case, as required
to conduct their respective businesses as currently conducted, except where the failure to obtain such license, authorization,
consent or approval or make such filing would not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect; neither the Company nor any of the Subsidiaries is in violation of, or in default under, or has received written
notice of any proceedings from any applicable governmental or regulatory authority relating to the revocation or adverse modification
of, any such license, authorization, consent or approval, except as described in the Registration Statement and the Prospectus
or where such violation, default, revocation or adverse modification would not, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Disclosure of Proceedings</U>. Except as described in the Registration Statement and the Prospectus, there is no legal,
governmental, administrative or regulatory investigation, action, suit, claim or proceeding pending or, to the Company&#8217;s
knowledge, threatened to which the Company or any of its Subsidiaries or any of their respective officers or directors is a party
(in their respective capacities as such), or to which any property of the Company or the Subsidiaries is or would reasonably be
expected to be subject, before any court, board, body, regulatory or non-regulatory administrative agency or competent authority,
which if determined adversely to the Company or any of the Subsidiaries would, individually or in the aggregate, have a Material
Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Independent
Accountants</U>. Ernst &amp; Young LLP, whose report on the consolidated financial statements of the Company and the Subsidiaries
is included in the Registration Statement and the Prospectus, are independent registered public accountants as required by the
Securities Act and the rules of the Public Company Accounting Oversight Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Financial
Statements</U>. The financial statements included in the Registration Statement and the Prospectus, together with the related
notes and schedules present fairly, in all material respects, the consolidated financial position of the Company and the
Subsidiaries as of the dates indicated and the consolidated results of operations, cash flows and changes in
stockholders&#8217; equity of the Company and the Subsidiaries for the periods specified, and have been prepared in material
compliance with the requirements of the Securities Act and the Exchange Act and in conformity with United States generally
accepted accounting principles (&#8220;<B>GAAP</B>&#8221;) applied on a consistent basis during the periods involved, and all
adjustments necessary for a fair presentation of results for such periods have been made; all pro forma financial information
included in the Registration Statement and the Prospectus presents fairly in all material respects the information shown
therein, has been prepared in accordance with the provisions of the Securities Act and the Rules and Regulations with respect
to pro forma financial information, has been properly compiled on the pro forma bases described therein in accordance with
the provisions of the Securities Act and the Rules and Regulations, and the assumptions used in the preparation thereof are
reasonable and the adjustments therein are appropriate to give effect to the transactions or circumstances referred to
therein; the summary and selected combined financial and operating data included in the Registration Statement and the
Prospectus present fairly in all material respects the information shown therein and such data have been compiled on a basis
consistent with the financial statements presented therein and the books and records of the Company; there are no financial
statements (historical or pro forma) that are required to be included in the Registration Statement or the Prospectus that
are not included as required; the Company and the Subsidiaries do not have any material liabilities or obligations, direct or
contingent (including any off-balance sheet obligations), that are not described in the Registration Statement and the
Prospectus; and any disclosures contained in the Registration Statement and the Prospectus that constitute &#8220;non-GAAP
financial measures&#8221; (as such term is defined by the rules and regulations of the Commission) comply with Regulation G
of the Exchange Act and Item 10 of Regulation S-K under the Securities Act, to the extent applicable. The interactive data in
eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement and the Prospectus
fairly presents the information called for in all material respects and has been prepared in accordance with the
Commission&#8217;s rules and guidelines applicable thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(t)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Stock Option Grants</U>. Except as would not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect, each stock option granted under any stock option plan of the Company or any Subsidiary (each, a &#8220;<B>Stock
Plan</B>&#8221;) was granted with a per share exercise price no less than the fair market value per Common Share, or, with respect
to incentive stock options granted to an employee who on the date of grant was the owner of stock possessing more than 10% of the
total combined voting power of all classes of stock of the Company (after taking into account the attribution of stock ownership
rules of Section 424(d) of the Internal Revenue Code of 1986, as amended (the &#8220;<B>Code</B>&#8221;), no less than 110% of
the fair market value per Common Share, on the grant date of such option, as determined by the Company&#8217;s board of directors,
and no such grant involved any &#8220;back-dating,&#8221; &#8220;forward-dating&#8221; or similar practice with respect to the
effective date of such grant; except as would not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect, each such option (i) was granted in compliance with applicable law and with the applicable Stock Plan(s), (ii)
was duly approved by the board of directors (or a duly authorized committee thereof or an officer of the Company duly authorized
by the board of directors or authorized committee thereof to make such grants) of the Company or such Subsidiary, as applicable,
and (iii) has been properly accounted for in the Company&#8217;s financial statements in accordance with GAAP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(u)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>No
Material Adverse Change</U>. Except as otherwise set forth or contemplated in, or subsequently incorporated by reference into,
the Registration Statement or the Prospectus, subsequent to the respective dates as of which information is given in the Registration
Statement and the Prospectus, there has not been (i) any material adverse change, or any development involving a prospective material
adverse change, in the business, properties, management, financial condition or results of operations of the Company and the Subsidiaries
taken as a whole (a &#8220;<B>Material Adverse Change</B>&#8221;), (ii) any transaction which is material to the Company and the
Subsidiaries taken as a whole, (iii) any obligation or liability, direct or contingent (including any off-balance sheet obligations),
incurred by the Company or any Subsidiary, which is material to the Company and the Subsidiaries taken as a whole, (iv) any change
in the capital stock or outstanding indebtedness of the Company or any Subsidiaries (other than borrowings in the ordinary course
of business under the Company&#8217;s Loan and Security Agreement, as amended on December 31, 2015 (as the same may be amended,
restated or replaced), and as described in the Registration Statement and the Prospectus, the issuance of Common Shares upon exercise
of stock options and warrants described as outstanding in the Registration Statement and the Prospectus, the grant in the ordinary
course of business of awards under equity incentive plans described in the Registration Statement and the Prospectus and the repurchase
by the Company or forfeiture of shares of common stock by the holder thereof pursuant to the terms of equity awards described
as outstanding in the Registration Statement and the Prospectus) or (v) any dividend or distribution of any kind declared, paid
or made on the capital stock of the Company or any Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Investment Company Act</U>. Neither the Company nor any Subsidiary is and, after giving effect to the offering and sale
of the Shares and the application of the proceeds thereof, neither of the Company nor any Subsidiary will be, an &#8220;investment
company&#8221; or an entity &#8220;controlled&#8221; by an &#8220;investment company,&#8221; as such terms are defined in the Investment
Company Act of 1940, as amended (the &#8220;<B>Investment Company Act</B>&#8221;), or a &#8220;passive foreign investment company&#8221;
or a &#8220;controlled foreign corporation,&#8221; as such terms are defined in the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(w)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Real Property</U>. Neither the Company nor the Subsidiaries own any real property; the Company and each of the Subsidiaries
have good and marketable title to all tangible personal property described in the Registration Statement and the Prospectus as
being owned by any of them, free and clear of all liens, claims, security interests or other encumbrances, except those that do
not materially interfere with the use or proposed use of such property by the Company or the Subsidiary, respectively, or as would
not materially or adversely affect the value of such property; all the property described in the Registration Statement and the
Prospectus as being held under lease by the Company or a Subsidiary is held thereby under valid, subsisting and enforceable leases,
except where such failure to hold such property would not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect and except that the enforcement thereof may be subject to (i) bankruptcy, insolvency, reorganization, receivership,
moratorium, fraudulent conveyance or other similar laws relating to creditor&#8217;s rights generally and (ii) general principles
of equity and the discretion of the court before which any proceeding therefor may be brought.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Intellectual
Property</U>. Except as disclosed in the Registration Statement and the Prospectus, the Company and the Subsidiaries own, or
have obtained valid and enforceable licenses for, or other rights to use, the patent applications, patents, trademarks,
trademark registrations, tradenames, service marks, copyrights, trade secrets and other unpatented or unpatentable
proprietary information necessary for, or used in the conduct, or the proposed conduct, of the business of the Company and
its Subsidiaries taken as a whole in the manner described in the Registration Statement and the Prospectus (collectively,
&#8220;<B>Intellectual Property</B>&#8221;), except as such failure to own or obtain rights would not result in a Material
Adverse Effect; except as disclosed in the Registration Statement and the Prospectus (i) to the knowledge of the Company,
there are no third parties who have any ownership rights in or to any Intellectual Property that is owned by the Company,
and, to the knowledge of the Company, no third party has any ownership right in or to any Intellectual Property in any field
of use that is exclusively licensed to the Company, other than the licensor to the Company of such Intellectual Property;
(ii) the Company has not received written notice of any material infringement by third parties of any Intellectual Property;
(iii) there is no pending or, to the Company&#8217;s knowledge, threatened action, suit, proceeding or claim by others
alleging that the Company is infringing, misappropriating, diluting or otherwise violating any rights of others with respect
to any Intellectual Property; (iv) there is no pending or, to the Company&#8217;s knowledge, threatened action, suit,
proceeding or claim by others challenging the validity, enforceability or scope of any of the patent or patent applications
owned or exclusively licensed by the Company included in the Intellectual Property; (v) the Company has not received written
notice of any claim of material infringement with any asserted rights of others with respect to any of the Company&#8217;s
products, proposed products, processes or Intellectual Property; (vi) except as would not reasonably be expected to result in
a Material Adverse Effect, the development, sale and any currently proposed use of any of the products, proposed products or
processes of the Company referred to in the Registration Statement and the Prospectus, in the current or proposed conduct of
the businesses of the Company in the manner and to the extent described in the Registration Statement and the Prospectus, do
not currently, and will not upon commercialization, infringe any right or valid patent claim of any third party; (vii) to the
knowledge of the Company, the parties prosecuting the patents and patent applications owned or licensed to the Company or
under which the Company has rights included in the Intellectual Property have complied with their duty of candor and
disclosure to the U.S. Patent and Trademark Office (the &#8220;<B>USPTO</B>&#8221;) in connection with such applications and
the Company is not aware of any facts required to be disclosed to the USPTO that were not disclosed to the USPTO and which
would preclude the grant of a patent in connection with any such application, or in the view of the Company could form a
reasonable basis of a finding of invalidity with respect to any patents that have issued with respect to such applications;
(viii) there is no prior art that may render any patent application within the Intellectual Property unpatentable that has
not been disclosed to the U.S. Patent and Trademark Office or of which the Company is otherwise aware; (ix) the product
candidates described in the Registration Statement and the Prospectus as under development by the Company or any Subsidiary
fall within the scope of the claims of one or more patents owned by, or exclusively licensed to, the Company or any
Subsidiary; and (x) to the Company&#8217;s knowledge, there is no patent or published patent application in the U.S. or other
jurisdiction which contains claims that dominate or may dominate the Intellectual Property or that interferes with the issued
or pending claims of any such Intellectual Property; the description of the Intellectual Property included or incorporated by
reference in the Registration Statement and the Prospectus is accurate and complete in all material respects and presents
fairly the information purported to be described therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(y)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Labor Matters</U>. Except for matters which would not, individually or in the aggregate, reasonably be expected to have
a Material Adverse Effect, there is (A) no unfair labor practice complaint pending or, to the Company&#8217;s knowledge, threatened
against the Company or any of the Subsidiaries before the National Labor Relations Board, and no grievance or arbitration proceeding
arising out of or under collective bargaining agreements is pending, or to the Company&#8217;s knowledge, threatened and (B) no
strike, labor dispute, slowdown or stoppage pending or, to the Company&#8217;s knowledge, threatened against the Company or any
of the Subsidiaries or against any of the principal suppliers, contractors or customers of the Company or any of its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(z)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Environmental
Matters</U>. The Company and the Subsidiaries are in compliance with, and hold all permits, authorizations and approvals
required under, Environmental Laws (as defined below), except to the extent that failure to so comply or to hold such
permits, authorizations or approvals would not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect; the Company and the Subsidiaries are not aware of any non-compliance with Environmental Laws, any past or
present events, conditions, activities, practices, actions, omissions or plans that could reasonably be expected to result in
non-compliance with Environmental Laws or any current liabilities under Environmental Laws, that could individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect; the Company and the Subsidiaries (i) are not the subject
of any investigation known to the Company, (ii) have not received any notice or claim, (iii) are not a party to any pending
or, to the Company&#8217;s knowledge, threatened action, suit or proceeding, (iv) are not bound by any judgment, decree or
order or (v) have not entered into any agreement, in each case relating to any alleged violation of any Environmental Law or
any actual or alleged release or threatened release or cleanup at any location of any Hazardous Materials (as defined below)
(as used herein, &#8220;<B>Environmental Law</B>&#8221; means any federal, state, local or foreign law, statute, ordinance,
rule, regulation, order, decree, judgment, injunction, permit, license, authorization or other legal requirement relating to
health, safety or the protection, cleanup or restoration of the environment or natural resources, including those relating to
the distribution, processing, generation, treatment, storage, disposal, transportation, other handling or release or
threatened release of Hazardous Materials, and &#8220;<B>Hazardous Materials</B>&#8221; means any material (including,
without limitation, pollutants, contaminants, hazardous or toxic substances or wastes) that is regulated by or may give rise
to liability under any Environmental Law).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(aa)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Tax Matters</U>. Except as described in the Registration Statement and the Prospectus, all material tax returns required
to be filed by the Company or any of the Subsidiaries have been filed (subject to permitted extensions), and all material taxes
and other assessments of a similar nature (whether imposed directly or through withholding) including any material interest, additions
to tax or penalties applicable thereto due or claimed to be due from such entities have been paid, other than those being contested
in good faith and for which adequate reserves have been provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(bb)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Insurance Matters</U>. The Company and each of the Subsidiaries maintain insurance covering their respective properties,
operations, personnel and businesses as the Company reasonably deems adequate; such insurance insures against such losses and risks
in accordance with customary industry practice to protect the Company and the Subsidiaries and their respective businesses and
which is commercially reasonably for the current conduct of their respective businesses; to the Company&#8217;s knowledge, all
such insurance is fully in force on the date hereof and is expected to be fully in force at each time of purchase, if any; neither
the Company nor any Subsidiary has reason to believe that it will not be able to (i) renew any such insurance as and when such
insurance expires or (ii) obtain comparable coverage from similar institutions as may be necessary or appropriate to conduct its
business as now conducted at a cost that would not, individually or in the aggregate, reasonably be expected to result in any Material
Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(cc)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination Notices</U>. Except as referred to or described in the Registration Statement or the Prospectus, neither
the Company nor any Subsidiary has sent or received any communication regarding termination of, or intent not to renew, any of
the contracts or agreements referred to or described in the Registration Statement or the Prospectus, and no such termination or
non-renewal has been threatened by the Company or any Subsidiary or, to the Company&#8217;s knowledge, any counterparty to any
such contract or agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(dd)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Internal
Controls</U>. The Company and the Subsidiaries maintain a system of &#8220;internal controls over financial reporting&#8221;
(as defined in Rule 13a-15(f) of the Exchange Act) that has been designed by, or under the supervision of, the
Company&#8217;s principal executive and principal financial officers, or persons performing similar functions, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with GAAP, including, but not limited to, internal accounting controls sufficient to provide
reasonable assurance that: (i) transactions are executed in accordance with management&#8217;s general or specific
authorizations; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with
GAAP and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management&#8217;s
general or specific authorization and any unauthorized access that could have a material effect on the Company&#8217;s
financial statements is timely detected; and (iv) the recorded accountability for assets is compared with existing assets at
reasonable intervals and appropriate action is taken with respect to any differences. Except as disclosed in the Registration
Statement and the Prospectus, there are no material weaknesses in the Company&#8217;s internal controls. The auditors and the
Audit Committee of the Board of Directors of the Company have been advised of: (i)&nbsp;all significant deficiencies and
material weaknesses in the design or operation of internal controls over financial reporting which have adversely affected or
are reasonably likely to adversely affect the Company&#8217;s ability to record, process, summarize and report financial
information; and (ii)&nbsp;any fraud, whether or not material, that involves management or other employees who have a
significant role in the Company&#8217;s internal controls over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ee)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Disclosure Controls</U>. The Company and its Subsidiaries have established and maintain and evaluate &#8220;disclosure
controls and procedures&#8221; (as such term is defined in Rule 13a-15 under the Exchange Act); such disclosure controls and procedures
have been designed to ensure that material information relating to the Company, including its consolidated subsidiaries, is made
known to the Company&#8217;s Chief Executive Officer and its Chief Financial Officer by others within those entities, and such
disclosure controls and procedures are effective to perform the functions for which they were established; no &#8220;significant
deficiencies&#8221; or &#8220;material weaknesses&#8221; (as such terms are defined in Rule 1-02(a)(4) of Regulation S-X under
the Act) of the Company were identified in connection with the audit by the Company&#8217;s independent registered public accountants
of the Company&#8217;s financial statements for the fiscal year ended December 31, 2019; since the date of the most recent evaluation
of such disclosure controls and procedures and internal controls, there have been no significant changes in internal controls or
in other factors that could significantly affect internal controls, including any corrective actions with regard to significant
deficiencies and material weaknesses and the principal executive officer and principal financial officer of the Company have made
all certifications required by the Sarbanes-Oxley Act of 2002 (the &#8220;<B>Sarbanes-Oxley Act</B>&#8221;) and any related rules
and regulations promulgated by the Commission, and the statements contained in each such certification are complete and correct
in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ff)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Sarbanes-Oxley Compliance</U>. The Company has taken all actions reasonably necessary to ensure that the Company and
the Subsidiaries and their respective officers and directors, in their capacities as such, are in compliance in all material respects
with the applicable provisions of the Sarbanes-Oxley Act and the rules and regulations promulgated in connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(gg)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Forward-Looking
Statements</U>. Each &#8220;forward-looking statement&#8221; (within the meaning of Section 27A of the Securities Act or
Section 21E of the Exchange Act) contained in the Registration Statement and the Prospectus has been made or reaffirmed with
a reasonable basis and in good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(hh)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Statistical and Market-Related Data</U>. All statistical and market-related data included in the Registration Statement
and the Prospectus are based on or derived from sources that the Company believes to be reliable and accurate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>FCPA, etc</U>. None of the Company, any of the Subsidiaries or any of their respective officers or directors or, to the
knowledge of the Company, any agent, employee or controlled affiliate of the Company or any of the Subsidiaries (i) has, directly
or indirectly, made, offered, promised, or authorized the unlawful payment or provision of anything of value to any foreign or
domestic government official or employee, including of any government-owned or controlled entity or of any public international
organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or
party official or candidate for political office, or (ii) is aware of or has taken any action, directly or indirectly, that would
result in a violation by such persons of the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder,
or the OECD Convention on Bribery of Foreign Public Officials in International Business Transactions; the Company, the Subsidiaries
and, to the knowledge of the Company, its controlled affiliates have instituted and maintain policies and procedures designed to
ensure continued compliance therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(jj)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Money Laundering Laws</U>. The operations of the Company and the Subsidiaries are and have been conducted at all times
in compliance with applicable financial recordkeeping and reporting requirements of the USA PATRIOT Act, the Bank Secrecy Act of
1970, as amended, the anti-money laundering statutes of all jurisdictions, the rules and regulations thereunder and any related
or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency having jurisdiction over
the Company (collectively, the &#8220;<B>Money Laundering Laws</B>&#8221;); and no action, suit or proceeding by or before any
court or governmental agency, authority or body or any arbitrator or non-governmental authority involving the Company or any of
the Subsidiaries with respect to the Money Laundering Laws is pending or, to the Company&#8217;s knowledge, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(kk)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Sanctions</U>.
None of the Company, any of the Subsidiaries or any of their respective officers or directors or, to the knowledge of the
Company, any agent, employee or controlled affiliate of the Company or any of the Subsidiaries is currently subject to or has
been subject in the last five (5) years to any sanctions administered or enforced by the Office of Foreign Assets Control of
the U.S. Treasury Department, the United Nations Security Council, the European Union, Her Majesty&#8217;s Treasury or any
other relevant sanctions authority (collectively, &#8220;<B>Sanctions</B>&#8221;), nor is the Company or any of its
Subsidiaries organized or resident in a country or territory that is the subject of Sanctions, including, without limitation,
Crimea, Cuba, Iran, North Korea, and Syria (each, a &#8220;<B>Sanctioned Country</B>&#8221;), and the Company will not
directly or indirectly use the proceeds of the offering of the Shares contemplated hereby, or lend, contribute or otherwise
make available such proceeds to any Subsidiary, joint venture partner or other person or entity (i) to fund or facilitate any
activities of or business with any person or country that, at the time of such funding or facilitation, is the subject of
Sanctions or a Sanctioned Country, respectively, or (ii) in any other manner that will result in a violation by any person
(including any person participating in the transaction, whether as underwriter, advisor, investor, or otherwise) of
Sanctions. For the past five years, none of the Company or any Subsidiaries has engaged in any direct or indirect dealings or
transactions with any person or country that, at the time of such dealing or transaction, was the subject of Sanctions or a
Sanctioned Country, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ll)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Patriot Act</U>. The Company acknowledges that, in accordance with the requirements of the USA PATRIOT Act, the Agent
is required to obtain, verify and record information that identifies their respective clients, including the Company, which information
may include the name and address of their respective clients, as well as other information that will allow the Agent to properly
identify their respective clients</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(mm)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Dividend Restrictions</U>. No Subsidiary is currently prohibited, directly or indirectly, from paying any dividends
to the Company, from making any other distribution on such Subsidiary&#8217;s capital stock, from repaying to the Company any loans
or advances to such Subsidiary from the Company or from transferring any of such Subsidiary&#8217;s property or assets to the Company
or any other Subsidiary of the Company, except as described in the Registration Statement and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(nn)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Health Regulatory Compliance</U>. The preclinical studies and clinical trials conducted by or, to the Company&#8217;s
knowledge, on behalf of the Company that are described in, or the results of which are referred to in, the Registration Statement
and the Prospectus were and, if still pending, are being conducted in all material respects in accordance with applicable local,
state and federal laws, rules and regulations, including, but not limited to, the Federal Food, Drug and Cosmetic Act and its applicable
implementing regulations; each description of the results of such studies contained in the Registration Statement and the Prospectus
is accurate in all material respects and fairly presents the data derived from such studies, and the Company is not aware of any
other studies the results of which the Company believes reasonably call into question the study results described or referred to
in the Registration Statement and the Prospectus; and except as disclosed in the Registration Statement and the Prospectus, neither
the Company nor any Subsidiary has received any written notices or other written correspondence from the Food and Drug Administration
of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug
or medical device regulatory agency having jurisdiction over the Company or any of its properties (collectively, the &#8220;<B>Regulatory
Agencies</B>&#8221;) requiring the termination, suspension or material adverse modification of any clinical trials that are described
or referred to in the Registration Statement and the Prospectus; and the Company and the Subsidiaries have each operated and currently
are in compliance with all applicable rules and regulations of the Regulatory Agencies except where the failure to be in compliance
would not be expected reasonably to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(oo)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Compliance
with Health Care Laws.</U> The Company and the Subsidiaries are, and since January 1, 2017 have been, in compliance with all
applicable Health Care Laws except where failure to be in compliance would not be expected reasonably to have a Material
Adverse Effect. For purposes of this Agreement, &#8220;<B>Health Care Laws</B>&#8221; means: (i) the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. &sect;&sect; 301 et seq.), and the regulations promulgated thereunder; (ii) all applicable federal,
state, local and foreign health care related fraud and abuse laws, including, without limitation, the U.S. Anti-Kickback
Statute (42 U.S.C. &sect; 1320a-7b(b)), the U.S. Civil False Claims Act (31 U.S.C. &sect;&sect; 3729 et seq.), the Federal
False Statements Law (42 U.S.C. &sect; 1320a-7b(a)), all criminal laws relating to health care fraud and abuse, including but
not limited to 18 U.S.C. &sect;&sect; 286 and 287, and the health care fraud criminal provisions under the U.S. Health
Insurance Portability and Accountability Act of 1996 (&#8220;<B>HIPAA</B>&#8221;) (42 U.S.C. &sect;&sect; 1320d et seq.), the
Civil Monetary Penalties Law (42 U.S.C. &sect; 1320a-7a), the exclusion laws (42 U.S.C. &sect; 1320a-7), the Medicare statute
(Title XVIII of the Social Security Act), and the Medicaid statute (Title XIX of the Social Security Act) and the regulations
promulgated pursuant to such statutes; (iii) HIPAA, as amended by the Health Information Technology for Economic and Clinical
Health Act (42 U.S.C. Section 17921 et seq.), and the regulations promulgated thereunder; (iv) the U.S. Physician Payments
Sunshine Act (42 U.S.C. &sect; 1320a-7h), and the regulations promulgated thereunder; and (v) any and all other applicable
health care laws and regulation applicable to the ownership, testing, development, manufacture, packaging, processing, use,
distribution, marketing, advertising, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any
product under development by the Company. Neither the Company nor the Subsidiaries has received written notice of any claim,
action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or
governmental or regulatory authority alleging that any product operation or activity is in material violation of any Health
Care Laws, and, to the Company&#8217;s knowledge, no such claim, action, suit, proceeding, hearing, enforcement,
investigation, arbitration or other action is threatened. Neither the Company nor the Subsidiaries is a party to any
corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or
imposed by any governmental or regulatory authority. Additionally, none of the Company or its Subsidiaries or any of their
respective officers or directors or, to the Company&#8217;s knowledge, any of their respective employees has been excluded,
suspended or debarred from participation in any U.S. federal health care program or human clinical research or, to the
knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could
reasonably be expected to result in debarment, suspension, or exclusion. The Company and the Subsidiaries have filed,
obtained, maintained or submitted all reports, documents, forms, notices, applications, records, claims, submissions and
supplements or amendments as required by the Health Care Laws, and all such reports, documents, forms, notices, applications,
records, claims, submissions and supplements or amendments were complete and accurate on the date filed in all material
respects (or were corrected or supplemented by a subsequent submission), except in each case, as would not reasonably be
expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(pp)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Cybersecurity
and Data Privacy</U>. The Company and the Subsidiaries&#8217; information technology assets and equipment, computers,
systems, networks, hardware, software, websites, applications, and databases (collectively, &#8220;<B>IT Systems</B>&#8221;)
are adequate for, and operate and perform in all material respects as required in connection with the operation of the
business of the Company and its subsidiaries as currently conducted, free and clear of all material bugs, errors, defects,
Trojan horses, time bombs, malware and other corruptants. The Company and the Subsidiaries have implemented and maintained
commercially reasonable controls, policies, procedures, and safeguards to maintain and protect their material confidential
information and the integrity, continuous operation, redundancy and security of all IT Systems and data (including all
Personal Data (as defined below) that is in the Company&#8217;s possession, and sensitive, confidential or regulated data
(collectively, the &#8220;<B>Confidential Data</B>&#8221;)) used in connection with their businesses, and there have been no
breaches, violations, outages or unauthorized uses of or accesses to same, except for those that have been remedied without
material cost or liability or the duty to notify any other person, nor any incidents under internal review or investigations
relating to the same. The Company and its subsidiaries are presently in material compliance with all applicable laws or
statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority,
internal policies and contractual obligations relating to the privacy and security of IT Systems and Confidential Data and to
the protection of such IT Systems and Confidential Data from unauthorized use, access, misappropriation or modification.
&#8220;<B>Personal Data</B>&#8221; means (i) a natural person&#8217;s name, street address, telephone number, e-mail address,
photograph, social security number or tax identification number, driver&#8217;s license number, passport number, credit card
number, bank information, or customer or account number; (ii) any information which would qualify as &#8220;personally
identifying information&#8221; under the Federal Trade Commission Act, as amended; (iii) Protected Health Information as
defined by HIPAA; (iv) &#8220;personal data&#8221; as defined by General Data Protection Regulation, and (v) any other piece
of information that allows the identification of such natural person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(qq)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Registration Rights</U>. The issuance and sale of the Shares as contemplated hereby will not cause any holder of any
shares of capital stock, securities convertible into or exchangeable or exercisable for capital stock or options, warrants or other
rights to purchase capital stock or any other securities of the Company to have any right to acquire any shares of capital stock
of the Company, except as have been otherwise waived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(rr)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Brokers</U>. Except pursuant to this Agreement, neither the Company nor any of the Subsidiaries has incurred any liability
for any finder&#8217;s or broker&#8217;s fee or agent&#8217;s commission in connection with the execution and delivery of this
Agreement or the consummation of the transactions contemplated hereby or by the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ss)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Price Stabilization or Manipulation; Compliance with Regulation M</U>. None of the Company, any of the Subsidiaries
or any of their respective directors, officers or affiliates has taken, directly or indirectly, any action designed, or which has
constituted or might reasonably be expected to cause or result in the stabilization or manipulation of the price of any security
of the Company to facilitate the sale or resale of the Shares in violation of Regulation M under the Exchange Act. The Company
acknowledges that the Agent may engage in passive market making transactions in the Shares on the Nasdaq Global Market in accordance
with Regulation M. The Common Shares are &#8220;actively traded securities&#8221; (as defined in Regulation M).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(tt)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>FINRA Matters</U>. To the Company&#8217;s knowledge, there are no affiliations or associations between (i) any member
of FINRA and (ii) the Company or any of the Company&#8217;s officers, directors or 5% or greater security holders or any beneficial
owner of the Company&#8217;s unregistered equity securities that were acquired at any time on or after the 180th day immediately
preceding the date the Registration Statement was initially filed with the Commission, except as disclosed in the Registration
Statement and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(uu)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>ERISA
Matters</U>. Except for matters which would not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect, each &#8220;employee benefit plan&#8221; (within the meaning of Section 3(3) of the Employee Retirement
Income Security Act of 1974, as amended, including the regulations and published interpretations thereunder
(&#8220;<B>ERISA</B>&#8221;)) for which the Company or any member of its &#8220;Controlled Group&#8221; (defined as any
organization that is a member of a controlled group of corporations within the meaning of Section 414 of the Code, including
its subsidiaries, would have liability (each a &#8220;<B>Plan</B>&#8221;) is in compliance in all material respects with all
presently applicable statutes, rules and regulations, including ERISA and the Code; (ii) with respect to each Plan subject to
Title IV of ERISA (a) no &#8220;reportable event&#8221; (as defined in Section 4043 of ERISA) has occurred for which the
Company or any member of its Controlled Group would have any liability; and (b) neither the Company nor any member of its
Controlled Group has incurred or expects to incur liability under Title IV of ERISA (other than for contributions to the Plan
or premiums payable to the Pension Benefit Guaranty Corporation, in each case in the ordinary course and without default);
(iii) no Plan which is subject to Section 412 of the Code or Section 302 of ERISA has failed to satisfy the minimum funding
standard within the meaning of such sections of the Code or ERISA; and (iv) each Plan that is intended to be qualified under
Section 401(a) of the Code is so qualified and nothing has occurred, whether by action or by failure to act, which would
reasonably be expected to cause the loss of such qualification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(vv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Stock Exchange Listing</U>. The Common Shares are registered pursuant to Section 12(b) of the Exchange Act and are listed
on the Nasdaq Global Market, and the Company has taken no action designed to, or likely to have the effect of, terminating the
registration of the Common Shares under the Exchange Act or delisting the Common Shares from the Nasdaq Global Market, nor has
the Company received any notification that the Commission or the Nasdaq Global Market is contemplating terminating such registration
or listing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ww)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Selecta
RUS</U>. Selecta (RUS) Limited Liability Company (i) does not own any Intellectual Property or assets that are material to the
Company&#8217;s business and (ii) does not have any operations that are material to the Company&#8217;s business or prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(xx)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Timely Filing</U>. The Company has timely made all filings required to be made under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(yy)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Other Underwriting Agreements</U>. The Company is not a party to any agreement with an agent or underwriter for any other
&#8220;at the market&#8221; or continuous equity transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any certificate signed
by any officer or representative of the Company or any of its subsidiaries and delivered to the Agent or counsel for the Agent
in connection with an issuance of Shares shall be deemed a representation and warranty by the Company to the Agent as to the matters
covered thereby on the date of such certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acknowledges that the Agent and, for purposes of the opinions to be delivered pursuant to </FONT><U>Section 4(o)</U> hereof,
counsel to the Company and counsel to the Agent, will rely upon the accuracy and truthfulness of the foregoing representations
and hereby consents to such reliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
3.</B></FONT> ISSUANCE AND SALE OF COMMON SHARES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Sale of Securities</U>. On the basis of the representations, warranties and agreements herein contained, but subject
to the terms and conditions herein set forth, the Company and the Agent agree that the Company may from time to time seek to sell
Shares through the Agent, acting as sales agent, or directly to the Agent, acting as principal, as follows, with an aggregate Sales
Price of up to the Maximum Program Amount, based on and in accordance with Issuance Notices as the Company may deliver, during
the Agency Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Split-Segment; Name: a2 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Mechanics of Issuances</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Issuance Notice</U>. Upon the terms and subject to the conditions set forth herein, on any Trading Day during the Agency Period
on which the conditions set forth in </FONT><U>Section 5(a)</U> and <U>Section 5(b)</U> shall have been satisfied, the Company
may exercise its right to request an issuance of Shares by delivering to the Agent an Issuance Notice; <I>provided, however</I>,
that (A) in no event may the Company deliver an Issuance Notice to the extent that (I) the sum of (x) the aggregate Sales Price
of the requested Issuance Amount, plus (y) the aggregate Sales Price of all Shares issued under all previous Issuance Notices effected
pursuant to this Agreement, would exceed the Maximum Program Amount; and (B) prior to delivery of any Issuance Notice, the period
set forth for any previous Issuance Notice shall have expired or been terminated. An Issuance Notice shall be considered delivered
on the Trading Day that it is received by e&#45;mail to the persons so identified in writing by the Agent and confirmed by the
Company by telephone (including a voicemail message to the persons so identified), with the understanding that, with adequate prior
written notice, the Agent may modify the list of such persons from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Agent
Efforts</U>. Upon the terms and subject to the conditions set forth in this Agreement, upon the receipt of an Issuance Notice,
the Agent will use its commercially reasonable efforts consistent with its normal sales and trading practices to place the Shares
with respect to which the Agent has agreed to act as sales agent, subject to, and in accordance with the information specified
in, the Issuance Notice, unless the sale of the Shares described therein has been suspended, cancelled or otherwise terminated
in accordance with the terms of this Agreement. For the avoidance of doubt, the parties to this Agreement may modify an Issuance
Notice at any time provided they both agree in writing to any such modification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Method
of Offer and Sale</U>. The Shares may be offered and sold (A) in negotiated transactions with the consent of the Company or (B)
by any other method permitted by law deemed to be an &#8220;at the market&#8221; offering as defined in Rule 415(a)(4) under the
Securities Act, including block transactions, sales made directly on the Principal Market or sales made into any other existing
trading market of the Common Shares. Nothing in this Agreement shall be deemed to require either party to agree to the method of
offer and sale specified in the preceding sentence, and (except as specified in clause (A) above) the method of placement of any
Shares by the Agent shall be at the Agent&#8217;s discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Confirmation
to the Company</U>. If acting as sales agent hereunder, the Agent will provide written confirmation to the Company no later than
the opening of the Trading Day next following the Trading Day on which it has placed Shares hereunder setting forth the number
of shares sold on such Trading Day, the corresponding Sales Price and the Issuance Price payable to the Company in respect thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Settlement</U>.
Each issuance of Shares will be settled on the applicable Settlement Date for such issuance of Shares and, subject to the
provisions of </FONT><U>Section 5</U>, on or before each Settlement Date, the Company will, or will cause its transfer agent
to, electronically transfer the Shares being sold by crediting the Agent or its designee&#8217;s account at The Depository
Trust Company through its Deposit/Withdrawal At Custodian (DWAC) System, or by such other means of delivery as may be
mutually agreed upon by the parties hereto and, upon receipt of such Shares, which in all cases shall be freely tradable,
transferable, registered shares in good deliverable form, the Agent will deliver, by wire transfer of immediately available
funds, the related Issuance Price in same day funds delivered to an account designated by the Company prior to the Settlement
Date. The Company may sell Shares to the Agent as principal at a price agreed upon at each relevant time Shares are sold
pursuant to this Agreement (each, a &#8220;<B>Time of Sale</B>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Suspension
or Termination of Sales</U>. Consistent with standard market settlement practices, the Company or the Agent may, upon notice to
the other party hereto in writing or by telephone (confirmed immediately by verifiable email), suspend any sale of Shares, and
the period set forth in an Issuance Notice shall immediately terminate; <I>provided, however</I>, that (A) such suspension and
termination shall not affect or impair either party&#8217;s obligations with respect to any Shares placed or sold hereunder prior
to the receipt of such notice; (B) if the Company suspends or terminates any sale of Shares after the Agent confirms such sale
to the Company, the Company shall still be obligated to comply with </FONT><U>Section 3(b)(v)</U> with respect to such Shares;
and (C) if the Company defaults in its obligation to deliver Shares on a Settlement Date, the Company agrees that it will hold
the Agent harmless against any loss, claim, damage or expense (including, without limitation, penalties, interest and reasonable
legal fees and expenses), as incurred, arising out of or in connection with such default by the Company. The parties hereto acknowledge
and agree that, in performing its obligations under this Agreement, the Agent may borrow Common Shares from stock lenders in the
event that the Company has not delivered Shares to settle sales as required by subsection (v) above, and may use the Shares to
settle or close out such borrowings. The Company agrees that no such notice shall be effective against the Agent unless it is made
to the persons identified in writing by the Agent pursuant to <U>Section 3(b)(i)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Guarantee of Placement, Etc.</U> The Company acknowledges and agrees that (A) there can be no assurance that the Agent will be
successful in placing Shares and (B) the Agent will incur no liability or obligation to the Company or any other Person if it does
not sell Shares, and (C)&nbsp;the Agent shall be under no obligation to purchase Shares on a principal basis pursuant to this Agreement,
except as otherwise specifically agreed by the Agent and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(viii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Material
Non-Public Information.</U> Notwithstanding any other provision of this Agreement, the Company and the Agent agree that the Company
shall not deliver any Issuance Notice to the Agent, and the Agent shall not be obligated to place any Shares, during any period
in which the Company is in possession of material non-public information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Fees</U>. As compensation for services rendered, the Company shall pay to the Agent, on the applicable Settlement Date,
the Selling Commission for the applicable Issuance Amount (including with respect to any suspended or terminated sale pursuant
to <U>Section 3(b)(vi))</U> by the Agent deducting the Selling Commission from the applicable Issuance Amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT> <U>Expenses</U>.
The Company agrees to pay all costs, fees and expenses incurred in connection with the performance of its obligations
hereunder and in connection with the transactions contemplated hereby, including without limitation (i)&nbsp;all expenses
incident to the issuance and delivery of the Shares (including all printing and engraving costs), (ii)&nbsp;all fees and
expenses of the registrar and transfer agent of the Shares, (iii)&nbsp;all necessary issue, transfer and other stamp taxes in
connection with the issuance and sale of the Shares, (iv)&nbsp;all fees and expenses of the Company&#8217;s counsel,
independent public or certified public accountants and other advisors, (v)&nbsp;all costs and expenses incurred in connection
with the preparation, printing, filing, shipping and distribution of the Registration Statement (including financial
statements, exhibits, schedules, consents and certificates of experts), the Prospectus, any Free Writing Prospectus (as
defined below) prepared by or on behalf of, used by, or referred to by the Company, and all amendments and supplements
thereto, and this Agreement, (vi)&nbsp;all filing fees, attorneys&#8217; fees and expenses incurred by the Company or the
Agent in connection with qualifying or registering (or obtaining exemptions from the qualification or registration of) all or
any part of the Shares for offer and sale under the state securities or blue sky laws or the provincial securities laws of
Canada, and, if requested by the Agent, preparing and printing a &#8220;Blue Sky Survey&#8221; or memorandum and a
&#8220;Canadian wrapper,&#8221; and any supplements thereto, advising the Agent of such qualifications, registrations,
determinations and exemptions, (vii) the reasonable fees and documented and disbursements of the Agent&#8217;s counsel,
including&nbsp;the reasonable and documented fees and expenses of counsel for the Agent in connection with, FINRA review, if
any, and approval of the Agent&#8217;s participation in the offering and distribution of the Shares, (viii) the filing fees
incident to FINRA review, if any, (ix)&nbsp;the costs and expenses of the Company relating to investor presentations on any
&#8220;road show&#8221; undertaken in connection with the marketing of the offering of the Shares, including, without
limitation, expenses associated with the preparation or dissemination of any electronic road show, expenses associated with
the production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road
show presentations with the prior approval of the Company, travel and lodging expenses of the representatives, employees and
officers of the Company and of the Agent and any such consultants, and the cost of any aircraft chartered in connection with
the road show and (x)&nbsp;the fees and expenses associated with listing the Shares on the Nasdaq Global Market. The fees and
disbursements of Agent&#8217;s counsel pursuant to subsections (vi), (vii) and (viii), above shall not exceed (A) $50,000 in
connection with execution of this Agreement and (B) $15,000 in connection with each Triggering Event Date (as defined below)
on which the Company is required to provide a certificate pursuant to Section 4(o).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
4.</B></FONT> ADDITIONAL COVENANTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company covenants
and agrees with the Agent as follows, in addition to any other covenants and agreements made elsewhere in this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Exchange
Act Compliance</U>. During the Agency Period, the Company shall (i) file, on a timely basis, with the Commission all reports
and documents required to be filed under Section 13, 14 or 15 of the Exchange Act in the manner and within the time periods
required by the Exchange Act and (ii) either (A) include in its quarterly reports on Form 10-Q and its annual reports on Form
10-K, a summary detailing, for the relevant reporting period, (1) the number of Shares sold through the Agent pursuant to
this Agreement and (2) the net proceeds received by the Company from such sales or (B) prepare a prospectus supplement
containing, or include in such other filing permitted by the Securities Act or Exchange Act (each an &#8220;<B>Interim
Prospectus </B>Supplement&#8221;), such summary information and, at least once a quarter and subject to this <U>Section
4</U>, file such Interim Prospectus Supplement pursuant to Rule 424(b) under the Securities Act (and within the time periods
required by Rule 424(b) and Rule 430B under the Securities Act)).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Securities Act Compliance</U>. After the date of this Agreement, the Company shall promptly advise the Agent in writing
(i) of the receipt of any comments of, or requests for additional or supplemental information from, the Commission, (ii) of the
time and date of any filing of any post-effective amendment to the Registration Statement, any Rule 462(b) Registration Statement
or any amendment or supplement to the Prospectus, any Free Writing Prospectus, (iii) of the time and date that any post-effective
amendment to the Registration Statement or any Rule 462(b) Registration Statement becomes effective and (iv) of the issuance by
the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto,
any Rule 462(b) Registration Statement or any amendment or supplement to the Prospectus or of any order preventing or suspending
the use of any Free Writing Prospectus or the Prospectus, or of any proceedings to remove, suspend or terminate from listing or
quotation the Common Shares from any securities exchange upon which they are listed for trading or included or designated for quotation,
or of the threatening or initiation of any proceedings for any of such purposes. If the Commission shall enter any such stop order
at any time, the Company will use its reasonable best efforts to obtain the lifting of such order as soon as practicable. Additionally,
the Company agrees that it shall comply with the provisions of Rule 424(b) and Rule 433, as applicable, under the Securities Act
and will use its reasonable efforts to confirm that any filings made by the Company under such Rule 424(b) or Rule 433 were received
in a timely manner by the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Amendments and Supplements to the Prospectus and Other Securities Act Matters</U>. If any event shall occur or condition
exist as a result of which it is necessary to amend or supplement the Prospectus so that the Prospectus does not include an untrue
statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of
the circumstances when the Prospectus is delivered to a purchaser, not misleading, or if in the opinion of the Agent or counsel
for the Agent it is otherwise necessary to amend or supplement the Prospectus to comply with applicable law, including the Securities
Act, the Company agrees (subject to Section&nbsp;4(d) and Section 4(f)) to promptly prepare, file with the Commission and furnish
at its own expense to the Agent, amendments or supplements to the Prospectus so that the statements in the Prospectus as so amended
or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to
make the statements therein, in the light of the circumstances when the Prospectus is delivered to a purchaser, be misleading or
so that the Prospectus, as amended or supplemented, will comply with applicable law including the Securities Act. Neither the Agent&#8217;s
consent to, or delivery of, any such amendment or supplement shall constitute a waiver of any of the Company&#8217;s obligations
under Section 4(d) or Section 4(f).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Agent&#8217;s
Review of Proposed Amendments and Supplements</U>. During any period in which an Issuance Notice is pending, prior to
effecting any amendment or supplement to the Registration Statement (including any registration statement filed under
Rule&nbsp;462(b) under the Securities Act) or the Prospectus (excluding any amendment or supplement through incorporation of
any report filed under the Exchange Act) that affects the offer and sale of the Shares as contemplated by this Agreement, the
Company shall furnish to the Agent for review, a reasonable amount of time prior to the proposed time of filing or use
thereof, a copy of each such proposed amendment or supplement, and file with the Commission within the applicable period
specified in Rule 424(b) under the Securities Act any prospectus required to be filed pursuant to such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Use of Free Writing Prospectus</U>. Neither the Company nor the Agent has prepared, used, referred to or distributed,
or will prepare, use, refer to or distribute, without the other party&#8217;s prior written consent, any &#8220;written communication&#8221;
<FONT STYLE="text-underline-style: double">that</FONT> constitutes a &#8220;free writing prospectus&#8221; as such terms are defined
in Rule 405 <FONT STYLE="text-underline-style: double">under</FONT> the Securities Act <FONT STYLE="text-underline-style: double">with
respect to the offering contemplated by this Agreement</FONT> (any such free writing prospectus being referred to herein as a
&#8220;<B>Free Writing Prospectus</B>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Free Writing Prospectuses</U>. The Company shall furnish to the Agent for review, a reasonable amount of time prior to
the proposed time of filing or use thereof, a copy of each proposed free writing prospectus or any amendment or supplement thereto
to be prepared by or on behalf of, used by, or referred to by the Company and the Company shall not file, use or refer to any proposed
free writing prospectus or any amendment or supplement thereto without the Agent&#8217;s consent. The Company shall furnish to
the Agent, without charge, as many copies of any free writing prospectus prepared by or on behalf of, or used by the Company, as
the Agent may reasonably request. If at any time when a prospectus is required by the Securities Act (including, without limitation,
pursuant to Rule&nbsp;173(d)) to be delivered in connection with sales of the Shares (but in any event if at any time through and
including the date of this Agreement) there occurred or occurs an event or development as a result of which any free writing prospectus
prepared by or on behalf of, used by, or referred to by the Company conflicted or would conflict with the information contained
in the Registration Statement or included or would include an untrue statement of a material fact or omitted or would omit to state
a material fact necessary in order to make the statements therein, in the light of the circumstances prevailing at that subsequent
time, not misleading, the Company shall promptly amend or supplement such free writing prospectus to eliminate or correct such
conflict or so that the statements in such free writing prospectus as so amended or supplemented will not include an untrue statement
of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
prevailing at such subsequent time, not misleading, as the case may be; <I>provided, however</I>, that prior to amending or supplementing
any such free writing prospectus, the Company shall furnish to the Agent for review, a reasonable amount of time prior to the proposed
time of filing or use thereof, a copy of such proposed amended or supplemented free writing prospectus and the Company shall not
file, use or refer to any such amended or supplemented free writing prospectus without the Agent&#8217;s consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Filing of Agent Free Writing Prospectuses</U>. The Company shall not take any action that would result in the Agent or
the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus
prepared by or on behalf of the Agent that the Agent otherwise would not have been required to file thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Copies
of Registration Statement and Prospectus</U>. After the date of this Agreement through the last time that a prospectus is
required by the Securities Act (including, without limitation, pursuant to Rule&nbsp;173(d)) to be delivered in connection
with sales of the Shares, the Company agrees to furnish the Agent with copies (which may be electronic copies) of the
Registration Statement and each amendment thereto, and with copies of the Prospectus and each amendment or supplement thereto
in the form in which it is filed with the Commission pursuant to the Securities Act or Rule&nbsp;424(b) under the Securities
Act, both in such quantities as the Agent may reasonably request from time to time; and, if the delivery of a prospectus is
required under the Securities Act or under the blue sky or securities laws of any jurisdiction at any time on or prior to the
applicable Settlement Date for any period set forth in an Issuance Notice in connection with the offering or sale of the
Shares and if at such time any event has occurred as a result of which the Prospectus as then amended or supplemented would
include an untrue statement of a material fact or omit to state any material fact necessary in order to make the statements
therein, in the light of the circumstances under which they were made when such Prospectus is delivered, not misleading, or,
if for any other reason it is necessary during such same period to amend or supplement the Prospectus or to file under the
Exchange Act any document incorporated by reference in the Prospectus in order to comply with the Securities Act or the
Exchange Act, to notify the Agent and to request that the Agent suspend offers to sell Shares (and, if so notified, the Agent
shall cease such offers as soon as practicable); and if the Company decides to amend or supplement the Registration Statement
or the Prospectus as then amended or supplemented, to advise the Agent promptly by telephone (with confirmation in writing)
and to prepare and cause to be filed promptly with the Commission an amendment or supplement to the Registration Statement or
the Prospectus as then amended or supplemented that will correct such statement or omission or effect such compliance; <I>provided,
however</I>, that if during such same period the Agent is required to deliver a prospectus in respect of transactions in the
Shares, the Company shall promptly prepare and file with the Commission such an amendment or supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Blue Sky Compliance</U>. The Company shall cooperate with the Agent and counsel for the Agent to qualify or register
the Shares for sale under (or obtain exemptions from the application of) the state securities or blue sky laws or Canadian provincial
securities laws of those jurisdictions designated by the Agent, shall comply with such laws and shall continue such qualifications,
registrations and exemptions in effect so long as required for the distribution of the Shares. The Company shall not be required
to qualify as a foreign corporation or to take any action that would subject it to general service of process in any such jurisdiction
where it is not presently qualified or where it would be subject to taxation as a foreign corporation. The Company will advise
the Agent promptly of the suspension of the qualification or registration of (or any such exemption relating to) the Shares for
offering, sale or trading in any jurisdiction or any initiation or threat of any proceeding for any such purpose, and in the event
of the issuance of any order suspending such qualification, registration or exemption, the Company shall use its best efforts to
obtain the withdrawal thereof as soon as practicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Earnings Statement</U>. As soon as practicable, the Company will make generally available to its security holders and
to the Agent an earnings statement (which need not be audited) covering a period of at least twelve (12) months beginning with
the first fiscal quarter of the Company occurring after the date of this Agreement which shall satisfy the provisions of Section
11(a) of the Securities Act and Rule 158 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Listing; Reservation of Shares</U>. (a) The Company will maintain the listing of the Shares on the Principal Market and
(b) the Company will reserve and keep available at all times, free of preemptive rights, Shares for the purpose of enabling the
Company to satisfy its obligations pursuant to an outstanding Issuance Notice under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Transfer Agent</U>. The Company shall engage and maintain, at its expense, a registrar and transfer agent for the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Due Diligence</U>. During the term of this Agreement, the Company will reasonably cooperate with any reasonable due diligence
review conducted by the Agent in connection with the transactions contemplated hereby, including, without limitation, providing
information and making available documents and senior corporate officers, during normal business hours and at the Company&#8217;s
principal offices, as the Agent may reasonably request from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Representations and Warranties</U>. The Company acknowledges that each delivery of an Issuance Notice and each delivery
of Shares on a Settlement Date shall be deemed to be (i) an affirmation to the Agent that the representations and warranties of
the Company contained in or made pursuant to this Agreement are true and correct as of the date of such Issuance Notice or of such
Settlement Date, as the case may be, as though made at and as of each such date, except as may be disclosed in the Prospectus (including
any documents incorporated by reference therein and any supplements thereto), and (ii)&nbsp;an undertaking that the Company will
advise the Agent if any of such representations and warranties will not be true and correct as of the Settlement Date for the Shares
relating to such Issuance Notice, as though made at and as of each such date (except that such representations and warranties shall
be deemed to relate to the Registration Statement and the Prospectus as amended and supplemented relating to such Shares).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Deliverables at Triggering Event Dates; Certificates.</U> The Company agrees that on or prior to the date of the first
Issuance Notice and, during the term of this Agreement after the date of the first Issuance Notice, upon:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
filing of the Prospectus or the amendment or supplement of any Registration Statement or Prospectus (other than a prospectus supplement
relating solely to an offering of securities other than the Shares or a prospectus filed pursuant to <U>Section 4(a)(ii)(B)</U>),
by means of a post-effective amendment, sticker or supplement, but not by means of incorporation of documents by reference into
the Registration Statement or Prospectus;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
filing with the Commission of an annual report on Form 10-K or a quarterly report on Form 10-Q (including any Form 10-K/A or Form
10-Q/A containing amended financial information or a material amendment to the previously filed annual report on Form 10-K or quarterly
report on Form 10-Q), in each case, of the Company; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(C)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
filing with the Commission of a current report on Form 8-K of the Company containing amended financial information (other
than information &#8220;furnished&#8221; pursuant to Item 2.02 or 7.01 of Form 8-K or to provide disclosure pursuant to Item
8.01 of Form 8-K relating to reclassification of certain properties as discontinued operations in accordance with Statement
of Financial Accounting Standards No. 144) that is material to the offering of securities of the Company in the Agent&#8217;s
reasonable discretion (any such event, a &#8220;<B>Triggering Event Date</B>&#8221;), the Company shall furnish the Agent
(but in the case of clause (C) above only if the Agent reasonably determines that the information contained in such current
report on Form 8-K of the Company is material) with a certificate as of the Triggering Event Date, in the form and substance
satisfactory to the Agent and its counsel, substantially similar to the form previously provided to the Agent and its
counsel, modified, as necessary, to relate to the Registration Statement and the Prospectus as amended or supplemented, (A)
confirming that the representations and warranties of the Company contained in this Agreement are true and correct, (B) that
the Company has performed all of its obligations hereunder to be performed on or prior to the date of such certificate,
including those required to be performed pursuant to <U>Section 5(a)</U> hereof, and (C) containing any other certification
that the Agent shall reasonably request. The requirement to provide a certificate under this <U>Section 4(o)</U> shall be
automatically waived with no further action of the Agent or Company for any Triggering Event Date occurring at a time when no
Issuance Notice is pending or a suspension is in effect, which automatic waiver shall continue until the date the Company
delivers instructions for the sale of Shares hereunder (which for such calendar quarter shall be considered a Triggering
Event Date). Notwithstanding the foregoing, if the Company subsequently decides to sell Shares following a Triggering Event
Date when a suspension was in effect and did not provide the Agent with a certificate under this <U>Section 4(o)</U>, then
before the Company delivers the instructions for the sale of Shares or the Agent sells any Shares pursuant to such
instructions, the Company shall provide the Agent with a certificate in conformity with this <U>Section 4(o)</U> dated as of
the date that the instructions for the sale of Shares are issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Legal Opinions.</U> On or prior to the date of the first Issuance Notice and on or prior to each Triggering
Event Date with respect to which the Company is obligated to deliver a certificate pursuant to <U>Section 4(o)</U> for which no
waiver is applicable and excluding the date of this Agreement, the Company shall cause to be furnished, at the request of the Agent,
a negative assurances letter and the written legal opinion of Latham &amp; Watkins LLP, counsel to the Company, or other counsel
reasonably satisfactory to the Agent, and the written legal opinion of Wolf Greenfield, intellectual property counsel for the Company<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>4</SUP></FONT>,
each dated the date of delivery, in form and substance reasonably satisfactory to the Agent and its counsel, substantially similar
to the form previously provided to the Agent and its counsel, modified, as necessary, to relate to the Registration Statement and
the Prospectus as then amended or supplemented; <I>provided, however</I>, that the Company shall be required to furnish no more
than one legal opinion and negative assurance letter hereunder per each filing of an annual report on Form 10-K or a quarterly
report on Form 10-Q; <I>provided, further</I>, that the Company shall be required to furnish no more than one such opinion from
intellectual property counsel hereunder in any twelve (12) month period. In lieu of such opinions for subsequent periodic filings,
in the discretion of the Agent, the Company may furnish a reliance letter from such counsel to the Agent, permitting the Agent
to rely on a previously delivered opinion letter, modified as appropriate for any passage of time or Triggering Event Date (except
that statements in such prior opinion shall be deemed to relate to the Registration Statement and the Prospectus as amended or
supplemented as of such Triggering Event Date).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Comfort
Letter</U>. On or prior to the date of the first Issuance Notice and on or prior to each Triggering Event
Date with respect to which the Company is obligated to deliver a certificate pursuant to Section 4(o) and excluding the date
of this Agreement, the Company shall cause Ernst &amp; Young LLP, the independent registered public accounting firm who has
audited the financial statements included or incorporated by reference in the Registration Statement, to furnish the Agent a
comfort letter, dated the date of delivery, in form and substance reasonably satisfactory to the Agent and its counsel,
substantially similar to the form previously provided to the Agent and its counsel; provided, however, that any such comfort
letter will only be required on the Triggering Event Date specified to the extent that it contains financial statements filed
with the Commission under the Exchange Act and incorporated or deemed to be incorporated by reference into a Prospectus. If
requested by the Agent, the Company shall also cause a comfort letter to be furnished to the Agent within ten (10) Trading
Days of the date of occurrence of any material transaction or event requiring the filing of a current report on Form 8-K
containing material amended financial information of the Company, including the restatement of the Company&#8217;s financial
statements. The Company shall be required to furnish no more than one comfort letter hereunder per each filing of an annual
report on Form 10-K or a quarterly report on Form 10-Q.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Secretary&#8217;s
Certificate</U>. On or prior to the date of the first Issuance Notice, the Company shall furnish the Agent a certificate executed
by the Secretary of the Company, signing in such capacity, dated the date of delivery (i) certifying that attached thereto are
true and complete copies of the resolutions duly adopted by the Board of Directors of the Company authorizing the execution and
delivery of this Agreement and the consummation of the transactions contemplated hereby (including, without limitation, the issuance
of the Shares pursuant to this Agreement), which authorization shall be in full force and effect on and as of the date of such
certificate, (ii) certifying and attesting to the office, incumbency, due authority and specimen signatures of each Person who
executed <FONT STYLE="text-underline-style: double">this</FONT> Agreement for or on behalf of the Company and (iii) containing
any other certification that the Agent shall reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Agent&#8217;s
Own Account; Clients&#8217; Account</U>. The Company consents to the Agent trading, in compliance with applicable law, in the Common
Shares for the Agent&#8217;s own account and for the account of its clients at the same time as sales of the Shares occur pursuant
to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(t)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Investment
Limitation</U>. The Company shall not invest, or otherwise use the proceeds received by the Company from its sale of the Shares
in such a manner as would require the Company or any of its subsidiaries to register as an investment company under the Investment
Company Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(u)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Market
Activities</U>. The Company will not take, directly or indirectly, any action designed to or that might be reasonably expected
to cause or result in stabilization or manipulation of the price of the Shares or any other reference security, whether to facilitate
the sale or resale of the Shares or otherwise, and the Company will, and shall use commercially reasonable efforts to cause each
of its affiliates to, comply with all applicable provisions of Regulation M. If the limitations of Rule 102 of Regulation M (&#8220;<B>Rule
102</B>&#8221;) do not apply with respect to the Shares or any other reference security pursuant to any exception set forth in
Section (d) of Rule 102, then promptly upon notice from the Agent (or, if later, at the time stated in the notice), the Company
will, and shall use commercially reasonable efforts to cause each of its affiliates to, comply with Rule 102 as though such exception
were not available but the other provisions of Rule 102 (as interpreted by the Commission) did apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Split-Segment; Name: a3 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice
of Other Sale</U>. Without the written consent of the Agent, the Company will not, directly or indirectly, offer to sell,
sell, contract to sell, grant any option to sell or otherwise dispose of any Common Shares or securities convertible into or
exchangeable for Common Shares (other than Shares hereunder), warrants or any rights to purchase or acquire Common Shares, or
effect a reverse stock split, recapitalization, share consolidation, reclassification or similar transaction affecting the
outstanding Common Shares, during the period beginning on the third Trading Day immediately prior to the date on which any
Issuance Notice is delivered to the Agent hereunder and ending on the third Trading Day immediately following the Settlement
Date with respect to Shares sold pursuant to such Issuance Notice; and will not directly or indirectly enter into any other
&#8220;at the market&#8221; or continuous equity transaction offer to sell, sell, contract to sell, grant any option to sell
or otherwise dispose of any Common Shares (other than the Shares offered pursuant to this Agreement) or securities
convertible into or exchangeable for Common Shares, warrants or any rights to purchase or acquire, Common Shares prior to the
termination of this Agreement; <I>provided, however</I>, that such restrictions will not be required in connection with the
Company&#8217;s (i) issuance or sale of Common Shares, options to purchase Common Shares or Common Shares issuable upon the
exercise of options or other equity awards pursuant to any employee or director share option, incentive or benefit plan,
share purchase or ownership plan, long-term incentive plan, dividend reinvestment plan, inducement award under Nasdaq rules
or other compensation plan of the Company or its subsidiaries, whether now in effect or hereafter implemented , (ii) issuance
or sale of Common Shares pursuant to any dividend reinvestment plan that the Company may adopt from time to time, (iii)
issuance or sale of Common Shares issuable upon exchange, conversion or redemption of securities or the exercise or vesting
of warrants, options or other equity awards outstanding or disclosed in filings by the Company available on EDGAR or
otherwise in writing to the Agent , (iv) issuance or sale of up to 5% of the outstanding Common Shares, or securities
convertible into or exchangeable for Common Shares, immediately prior to giving effect to such issuance or sale, in
connection with mergers, acquisitions, other business combinations, joint ventures, collaborations or strategic arrangements
occurring after the date of this Agreement, (v) modification of any outstanding options, warrants of any rights to purchase
or acquire Common Shares, (vi) issuance or sale of Common Shares, or securities convertible into or exercisable for Common
Shares, offered and sold in a privately negotiated transaction to vendors, customers, strategic partners or potential
strategic partners conducted in a manner so as not to be integrated with the offering of Common Shares hereby and (vii) for
the avoidance of doubt, non-public discussions or negotiations with respect to any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
5.</B></FONT> CONDITIONS TO DELIVERY OF ISSUANCE NOTICES AND TO SETTLEMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Conditions Precedent to the Right of the Company to Deliver an Issuance Notice and the Obligation of the Agent to Sell
Shares</U>. The right of the Company to deliver an Issuance Notice hereunder is subject to the satisfaction, on the date of delivery
of such Issuance Notice, and the obligation of the Agent to use its commercially reasonable efforts to place Shares during the
applicable period set forth in the Issuance Notice is subject to the satisfaction, on each Trading Day during the applicable period
set forth in the Issuance Notice, of each of the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Accuracy
of the Company&#8217;s Representations and Warranties; Performance by the Company</U>. The Company shall have delivered the
certificate required to be delivered pursuant to <U>Section 4(o)</U> on or before the date on which delivery of such
certificate is required pursuant to <U>Section 4(o)</U>. The Company shall have performed, satisfied and complied with all
covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company at
or prior to such date, including, but not limited to, the covenants contained in <FONT STYLE="font-size: 10pt"><U>Section
4(p)</U>, <U>Section 4(q)</U> and <U>Section 4(r)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.4in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Injunction</U>. No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated
or endorsed by any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority
over the matters contemplated hereby that prohibits or directly and materially adversely affects any of the transactions contemplated
by this Agreement, and no proceeding shall have been commenced that may have the effect of prohibiting or materially adversely
affecting any of the transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.4in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Material
Adverse Changes</U>. Except as disclosed in the Prospectus, (a) there shall not have occurred any Material Adverse Change that,
in the judgment of the Agent, makes it impractical and inadvisable to market the Shares on the terms and in the manner contemplated
in the Prospectus; and (b) there shall not have occurred any downgrading, nor shall any notice have been given of any intended
or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in
the rating accorded any securities of the Company or any of its subsidiaries by any &#8220;nationally recognized statistical rating
organization&#8221; as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>No
Suspension of Trading in or Delisting of Common Shares; Other Events</U>. The trading of the Common Shares (including without limitation
the Shares) shall not have been suspended by the Commission, the Principal Market or FINRA and the Common Shares (including without
limitation the Shares) shall have been approved for listing or quotation on and shall not have been delisted from the Principal
Market. There shall not have occurred (and be continuing in the case of occurrences under clauses&nbsp;(i) and (ii)&nbsp;below)
any of the following: (i)&nbsp;trading or quotation in any of the Company&#8217;s securities shall have been suspended or limited
by the Commission or by the Principal Market, or trading in securities generally on either the Principal Market shall have been
suspended or limited, or minimum or maximum prices shall have been generally established on any of such stock exchanges by the
Commission or FINRA; (ii)&nbsp;a general banking moratorium shall have been declared by U.S. federal or New York authorities; or
(iii)&nbsp;there shall have occurred any outbreak or escalation of national or international hostilities or any crisis or calamity,
or any change in the United States or international financial markets, or any substantial change or development involving a prospective
substantial change in United States&#8217; or international political, financial or economic conditions, that, in any such case,
in the judgment of the Agent is material and adverse and makes it impractical and inadvisable to market the Shares in the manner
and on the terms described in the Prospectus or to enforce contracts for the sale of securities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Documents Required to be Delivered on each Issuance Notice Date</U>. The Agent&#8217;s obligation to use its commercially reasonable
efforts to place Shares hereunder shall additionally be conditioned upon the delivery to the Agent on or before the Issuance Notice
Date of a certificate in form and substance reasonably satisfactory to the Agent, executed by the Chief Executive Officer<FONT STYLE="text-underline-style: double">,
President or Chief Financial Officer</FONT> of the Company, to the effect that all conditions to the delivery of such Issuance
Notice shall have been satisfied as at the date of such certificate (which certificate shall not be required if the foregoing
representations shall be set forth in the Issuance Notice).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Misstatement or Material Omission</U>. Agent shall not have advised the Company that the Registration Statement or
Prospectus, or any amendment or supplement thereto, contains an untrue statement of fact that in the Agent&#8217;s reasonable opinion
is material, or omits to state a fact that in the Agent&#8217;s reasonable opinion is material and is required to be stated therein
or is necessary to make the statements therein not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Agent Counsel Legal Opinion</U>. Agent shall have received from Cooley LLP, counsel for Agent, such opinion or opinions,
on or before the date on which the delivery of the Company counsel legal opinion is required pursuant to Section 4(p), with respect
to such matters as Agent may reasonably require, and the Company shall have furnished to such counsel such documents as they request
for enabling them to pass upon such matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
6.</B></FONT> INDEMNIFICATION AND CONTRIBUTION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Indemnification
of the Agent</U>. The Company agrees to indemnify and hold harmless the Agent, its officers and employees, and each person,
if any, who controls the Agent within the meaning of the Securities Act or the Exchange Act against any loss, claim, damage,
liability or expense, as incurred, to which the Agent or such officer, employee or controlling person may become subject,
under the Securities Act, the Exchange Act, other federal or state statutory law or regulation, or the laws or regulations of
foreign jurisdictions where Shares have been offered or sold or at common law or otherwise (including in settlement of any
litigation), insofar as such loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below)
arises out of or is based upon (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the
Registration Statement, or any amendment thereto, including any information deemed to be a part thereof pursuant to
Rule&nbsp;430B under the Securities Act, or the omission or alleged omission therefrom of a material fact required to be
stated therein or necessary to make the statements therein not misleading or (ii)&nbsp;any untrue statement or alleged untrue
statement of a material fact contained in any Free Writing Prospectus that the Company has used, referred to or filed, or is
required to file, pursuant to Rule 433(d) of the Securities Act or the Prospectus (or any amendment or supplement thereto),
or the omission or alleged omission therefrom of a material fact necessary in order to make the statements therein, in the
light of the circumstances under which they were made, not misleading and to reimburse the Agent and each such officer,
employee and controlling person for any and all documented expenses (including the fees and disbursements of counsel chosen
by the Agent) as such expenses are reasonably incurred by the Agent or such officer, employee or controlling person in
connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense
or action; <I>provided, however</I>, that the foregoing indemnity agreement shall not apply to any loss, claim, damage,
liability or expense to the extent, but only to the extent, arising out of or based upon any untrue statement or alleged
untrue statement or omission or alleged omission made in reliance upon and in conformity with written information furnished
to the Company by the Agent expressly for use in the Registration Statement, any such Free Writing Prospectus or the
Prospectus (or any amendment or supplement thereto), it being understood and agreed that the only such information furnished
by the Agent to the Company consists of the information described in subsection (b) below. The indemnity agreement set forth
in this <FONT STYLE="font-size: 10pt"><U>Section 6(a)</U> shall be in addition to any liabilities that the Company may
otherwise have.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Indemnification of the Company, its Directors and Officers</U>.&nbsp; The Agent agrees to indemnify and hold harmless
the Company, each of its directors, each of its officers who signed the Registration Statement and each person, if any, who controls
the Company within the meaning of the Securities Act or the Exchange Act against any loss, claim, damage, liability or expense,
as incurred, to which the Company or any such director, officer or controlling person may become subject, under the Securities
Act, the Exchange Act, or other federal or state statutory law or regulation, or the laws or regulations of foreign jurisdictions
where Shares have been offered or sold or at common law or otherwise (including in settlement of any litigation), arises out of
or is based upon (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement,
or any amendment thereto, including any information deemed to be a part thereof pursuant to Rule&nbsp;430B under the Securities
Act, or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements
therein not misleading; or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in any Free
Writing Prospectus that the Company has used, referred to or filed, or is required to file, pursuant to Rule&nbsp;433(d)&nbsp;of
the Securities Act or the Prospectus (or any amendment or supplement thereto), or the omission or alleged omission therefrom of
a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made,
not misleading; but, for each of (i) and (ii) above, only to the extent arising out of or based upon any untrue statement or alleged
untrue statement or omission or alleged omission made in reliance upon and in conformity with written information furnished to
the Company by the Agent expressly for use in the Registration Statement, any such Free Writing Prospectus or the Prospectus (or
any amendment or supplement thereto), it being understood and agreed that the only such information furnished by the Agent to the
Company consists of the information set forth in the first sentence of the ninth paragraph under the caption &#8220;Plan of Distribution&#8221;
in the Prospectus, and to reimburse the Company and each such director, officer and controlling person for any and all expenses
(including the fees and disbursements of counsel chosen by the Company) as such expenses are reasonably incurred by the Company
or such officer, director or controlling person in connection with investigating, defending, settling, compromising or paying any
such loss, claim, damage, liability, expense or action. The indemnity agreement set forth in this Section&nbsp;6(b)&nbsp;shall
be in addition to any liabilities that the Agent or the Company may otherwise have.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Notifications
and Other Indemnification Procedures</U>. Promptly after receipt by an indemnified party under this <U>Section 6</U> of
notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against an
indemnifying party under this <U>Section 6</U>, notify the indemnifying party in writing of the commencement thereof, but the
omission so to notify the indemnifying party will not relieve it from any liability which it may have to any indemnified
party for contribution or otherwise than under the indemnity agreement contained in this <U>Section 6</U> or to the extent it
is not prejudiced as a proximate result of such failure. In case any such action is brought against any indemnified party and
such indemnified party seeks or intends to seek indemnity from an indemnifying party, the indemnifying party will be entitled
to participate in, and, to the extent that it shall elect, jointly with all other indemnifying parties similarly notified, by
written notice delivered to the indemnified party promptly after receiving the aforesaid notice from such indemnified party,
to assume the defense thereof with counsel reasonably satisfactory to such indemnified party; <I>provided, however</I>, if
the defendants in any such action include both the indemnified party and the indemnifying party and the indemnified party
shall have reasonably concluded that a conflict may arise between the positions of the indemnifying party and the indemnified
party in conducting the defense of any such action or that there may be legal defenses available to it and/or other
indemnified parties which are different from or additional to those available to the indemnifying party, the indemnified
party or parties shall have the right to select separate counsel to assume such legal defenses and to otherwise participate
in the defense of such action on behalf of such indemnified party or parties. Upon receipt of notice from the indemnifying
party to such indemnified party of such indemnifying party&#8217;s election so to assume the defense of such action and
approval by the indemnified party of counsel, the indemnifying party will not be liable to such indemnified party under this <FONT STYLE="font-size: 10pt"><U>Section
6</U> for any reasonable and documented legal or other expenses subsequently incurred by such indemnified party in connection
with the defense thereof unless (i)&nbsp;the indemnified party shall have employed separate counsel in accordance with the
proviso to the preceding sentence (it being understood, however, that the indemnifying party shall not be liable for the fees
and expenses of more than one separate counsel (together with local counsel), representing the indemnified parties who are
parties to such action), which counsel (together with any local counsel) for the indemnified parties shall be selected by
Jefferies LLC (in the case of counsel for the indemnified parties referred to in <U>Section 6(a)</U> above) or the Company
(in the case of counsel for the indemnified parties referred to in <U>Section 6(b) </U>above), (ii)&nbsp;the indemnifying
party shall not have employed counsel reasonably satisfactory to the indemnified party to represent the indemnified party
within a reasonable time after notice of commencement of the action or (iii) the indemnifying party has authorized in writing
the employment of counsel for the indemnified party at the expense of the indemnifying party, in each of which cases the fees
and expenses of counsel shall be at the expense of the indemnifying party and shall be paid as they are incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Settlements</U>. The indemnifying party under this <U>Section 6</U> shall not be liable for any settlement of any proceeding
effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying
party agrees to indemnify the indemnified party against any loss, claim, damage, liability or expense by reason of such settlement
or judgment. Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party
to reimburse the indemnified party for fees and expenses of counsel as contemplated by <U>Section 6(c)</U> hereof, the indemnifying
party agrees that it shall be liable for any settlement of any proceeding effected without its written consent if (i)&nbsp;such
settlement is entered into more than 30&nbsp;days after receipt by such indemnifying party of the aforesaid request and (ii)&nbsp;such
indemnifying party shall not have reimbursed the indemnified party in accordance with such request prior to the date of such settlement.
No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement, compromise or consent
to the entry of judgment in any pending or threatened action, suit or proceeding in respect of which any indemnified party is or
could have been a party and indemnity was or could have been sought hereunder by such indemnified party, unless such settlement,
compromise or consent includes an unconditional release of such indemnified party from all liability on claims that are the subject
matter of such action, suit or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Contribution</U>.
If the indemnification provided for in this <U>Section 6</U> is for any reason held to be unavailable to or otherwise
insufficient to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities or expenses
referred to therein, then each indemnifying party shall contribute to the aggregate amount paid or payable by such
indemnified party, as incurred, as a result of any losses, claims, damages, liabilities or expenses referred to therein
(i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and
the Agent, on the other hand, from the offering of the Shares pursuant to this Agreement or (ii)&nbsp;if the allocation
provided by clause&nbsp;(i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not
only the relative benefits referred to in clause&nbsp;(i) above but also the relative fault of the Company, on the one hand,
and the Agent, on the other hand, in connection with the statements or omissions which resulted in such losses, claims,
damages, liabilities or expenses, as well as any other relevant equitable considerations. The relative benefits received by
the Company, on the one hand, and the Agent, on the other hand, in connection with the offering of the Shares pursuant to
this Agreement shall be deemed to be in the same respective proportions as the total gross proceeds from the offering of the
Shares (before deducting expenses) received by the Company bear to the total commissions received by the Agent. The relative
fault of the Company, on the one hand, and the Agent, on the other hand, shall be determined by reference to, among other
things, whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a
material fact relates to information supplied by the Company, on the one hand, or the Agent, on the other hand, and the
parties&#8217; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or
omission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
amount paid or payable by a party as a result of the losses, claims, damages, liabilities and expenses referred to above shall
be deemed to include, subject to the limitations set forth in </FONT><U>Section 6(c)</U>, any reasonable and documented legal or
other fees or expenses reasonably incurred by such party in connection with investigating or defending any action or claim. The
provisions set forth in <U>Section 6(c)</U> with respect to notice of commencement of any action shall apply if a claim for contribution
is to be made under this <U>Section 6(e)</U>; <I>provided, however</I>, that no additional notice shall be required with respect
to any action for which notice has been given under <U>Section 6(c)</U> for purposes of indemnification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company and the Agent agree that it would not be just and equitable if contribution pursuant to this </FONT><U>Section 6(e)</U>
were determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations
referred to in this <U>Section 6(e)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the provisions of this </FONT><U>Section 6(e)</U>, the Agent shall not be required to contribute any amount in excess of the Selling
Commission received by the Agent in connection with the offering contemplated hereby. No person guilty of fraudulent misrepresentation
(within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution from any person who was not
guilty of such fraudulent misrepresentation. For purposes of this <U>Section 6(e)</U>, each officer and employee of the Agent and
each person, if any, who controls the Agent within the meaning of the Securities Act or the Exchange Act shall have the same rights
to contribution as the Agent, and each director of the Company, each officer of the Company who signed the Registration Statement,
and each person, if any, who controls the Company within the meaning of the Securities Act and the Exchange Act shall have the
same rights to contribution as the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Section 7. TERMINATION &amp;
SURVIVAL</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Term</U>. Subject to the provisions of this <U>Section 7</U>, the term of this Agreement shall continue from the date
of this Agreement until the end of the Agency Period, unless earlier terminated by the parties to this Agreement pursuant to this
<U>Section 7</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Termination;
Survival Following Termination</U>. (i) Either party may terminate this Agreement prior to the end of the Agency Period, by
giving written notice as required by this Agreement, upon ten (10) Trading Days&#8217; notice to the other party; <I>provided</I>
that, (A) if the Company terminates this Agreement after the Agent confirms to the Company any sale of Shares, the Company
shall remain obligated to comply with <U>Section 3(b)(v)</U> with respect to such Shares and (B) <U>Section 2</U>, <U>Section
3(d)</U>, <U>Section 6</U>, <U>Section 7</U> and <U>Section 8</U> shall survive termination of this Agreement. If termination
shall occur prior to the Settlement Date for any sale of Shares, such sale shall nevertheless settle in accordance with the
terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to the survival provision of </FONT><U>Section 7(b)(i)</U>, the respective indemnities, agreements, representations, warranties
and other statements of the Company, of its officers and of the Agent set forth in or made pursuant to this Agreement will remain
in full force and effect, regardless of any investigation made by or on behalf of the Agent or the Company or any of its or their
partners, officers or directors or any controlling person, as the case may be, and, anything herein to the contrary notwithstanding,
will survive delivery of and payment for the Shares sold hereunder and any termination of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
8.</B></FONT> MISCELLANEOUS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Press Releases and Disclosure</U>. The Company may issue a press release describing the material terms of the transactions
contemplated hereby as soon as practicable following the date of this Agreement, and may file with the Commission a Current Report
on Form&nbsp;8-K, with this Agreement attached as an exhibit thereto, describing the material terms of the transactions contemplated
hereby, and the Company shall consult with the Agent prior to making such disclosures, and the parties hereto shall use all commercially
reasonable efforts, acting in good faith, to agree upon a text for such disclosures that is reasonably satisfactory to all parties
hereto. No party hereto shall issue thereafter any press release or like public statement (including, without limitation, any disclosure
required in reports filed with the Commission pursuant to the Exchange Act) related to this Agreement or any of the transactions
contemplated hereby without the prior written approval of the other party hereto, except as may be necessary or appropriate in
the reasonable opinion of the party seeking to make disclosure to comply with the requirements of applicable law or stock exchange
rules and except for the disclosure required pursuant to <U>Section 4(a)</U> of this Agreement in the Company&#8217;s quarterly
reports on Form 10-Q or annual reports on Form 10-K. If any such press release or like public statement is so required, the party
making such disclosure shall consult with the other party prior to making such disclosure, and the parties shall use all commercially
reasonable efforts, acting in good faith, to agree upon a text for such disclosure that is reasonably satisfactory to all parties
hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>No
Advisory or Fiduciary Relationship</U>. The Company acknowledges and agrees that (i) the transactions contemplated by this
Agreement, including the determination of any fees, are arm&#8217;s-length commercial transactions between the Company and
the Agent, (ii) when acting as a principal under this Agreement, the Agent is and has been acting solely as a principal is
not the agent or fiduciary of the Company, or its stockholders, creditors, employees or any other party, (iii) the Agent has
not assumed nor will assume an advisory or fiduciary responsibility in favor of the Company with respect to the transactions
contemplated hereby or the process leading thereto (irrespective of whether the Agent has advised or is currently advising
the Company on other matters) and the Agent does not have any obligation to the Company with respect to the transactions
contemplated hereby except the obligations expressly set forth in this Agreement, (iv) the Agent and its affiliates may be
engaged in a broad range of transactions that involve interests that differ from those of the Company, and (v) the Agent has
not provided any legal, accounting, regulatory or tax advice with respect to the transactions contemplated hereby and the
Company has consulted its own legal, accounting, regulatory and tax advisors to the extent it deemed appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Research Analyst Independence</U>. The Company acknowledges that the Agent&#8217;s research analysts and research departments
are required to and should be independent from their respective investment banking divisions and are subject to certain regulations
and internal policies, and as such the Agent&#8217;s research analysts may hold views and make statements or investment recommendations
and/or publish research reports with respect to the Company or the offering that differ from the views of their respective investment
banking divisions. The Company understands that the Agent is a full service securities firm and as such from time to time, subject
to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short
positions in debt or equity securities of the companies that may be the subject of the transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notices</U>. All communications hereunder shall be in writing and shall be mailed, hand delivered or telecopied and confirmed
to the parties hereto as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to the </FONT>Agent:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.5in">Jefferies LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.5in">520 Madison
Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.5in">New&nbsp;York, NY 10022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.5in">Facsimile:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.5in">Attention:
General Counsel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.5in">with a copy (which shall not
constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.5in">Cooley LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.5in">55 Hudson
Yards</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.5in">New&nbsp;York, NY 10001</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.5in">Facsimile: (212) 479-6275</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.5in">Attention: Daniel I. Goldberg and Joshua A. Kaufman</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.5in">If to the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selecta
Biosciences, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT>480 Arsenal Way</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Watertown,
MA 02472</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT>Attention: David Abraham</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.5in">with a copy (which shall not
constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Latham &amp; Watkins LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">200 Clarendon Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Boston, MA 02116</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Attention: Peter N. Handrinos and Wesley C. Holmes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
party hereto may change the address for receipt of communications by giving written notice to the others in accordance with this
</FONT><U>Section 8(d)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Successors</U>. This Agreement will inure to the benefit of and be binding upon the parties hereto, and to the benefit
of the employees, officers and directors and controlling persons referred to in <U>Section 6</U>, and in each case their respective
successors, and no other person will have any right or obligation hereunder. The term &#8220;<B>successors</B>&#8221; shall not
include any purchaser of the Shares as such from the Agent merely by reason of such purchase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Partial Unenforceability</U>. The invalidity or unenforceability of any Article, Section, paragraph or provision of this
Agreement shall not affect the validity or enforceability of any other Article, Section, paragraph or provision hereof. If any
Article, Section, paragraph or provision of this Agreement is for any reason determined to be invalid or unenforceable, there shall
be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Governing Law Provisions</U>. This Agreement shall be governed by and construed in accordance with the internal laws
of the State of New York applicable to agreements made and to be performed in such state. Any legal suit, action or proceeding
arising out of or based upon this Agreement or the transactions contemplated hereby may be instituted in the federal courts of
the United States of America located in the Borough of Manhattan in the City of New York or the courts of the State of New York
in each case located in the Borough of Manhattan in the City of New York (collectively, the &#8220;<B>Specified Courts</B>&#8221;),
and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement
of a judgment of any such court, as to which such jurisdiction is non-exclusive) of such courts in any such suit, action or proceeding.
Service of any process, summons, notice or document by mail to such party&#8217;s address set forth above shall be effective service
of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive
any objection to the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally
waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any such court
has been brought in an inconvenient forum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>General
Provisions</U>. This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior
written or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter
hereof. This Agreement may be executed in two or more counterparts, each one of which shall be an original, with the same
effect as if the signatures thereto and hereto were upon the same instrument, and may be delivered by facsimile transmission
or by electronic delivery of a <FONT STYLE="font-size: 10pt">portable document format (PDF) file. This Agreement may not be
amended or modified unless in writing by all of the parties hereto, and no condition herein (express or implied) may be
waived unless waived in writing by each party whom the condition is meant to benefit. The Article and Section headings herein
are for the convenience of the parties only and shall not affect the construction or interpretation of this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page Immediately Follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I></I></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the foregoing is
in accordance with your understanding of our agreement, kindly sign and return to the Company the enclosed copies hereof, whereupon
this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SELECTA
    BIOSCIENCES, INC.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 46%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Carsten Brunn, Ph.D.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: &nbsp;&nbsp;&nbsp;Carsten Brunn, Ph.D.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;President and Chief Executive Officer</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The foregoing Agreement is hereby confirmed
and accepted by the Agent in New York, New York as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JEFFERIES
    LLC</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%">/s/ Michael Magarro</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Michael Magarro</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Managing Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ISSUANCE NOTICE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[Date]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jefferies LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">520 Madison Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, New York 10022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attn: [__________]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Reference is made to the Open Market Sale
Agreement<SUP>SM</SUP> between Selecta Biosciences, Inc. (the &#8220;<B>Company</B>&#8221;) and Jefferies LLC (the &#8220;<B>Agent</B>&#8221;)
dated as of August 6, 2020. The Company confirms that all conditions to the delivery of this Issuance Notice are satisfied as of
the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of Delivery of Issuance Notice (determined pursuant to </FONT><U>Section 3(b)(i)</U>): _______________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issuance Amount (equal to the total Sales Price for such Shares):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 25%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif">Number of days in selling period:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">First date of selling period:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Last date of selling period:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif">Settlement Date(s) if other than standard T+2 settlement:</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Floor Price Limitation (in no event less
than $1.00 without the prior written consent of the Agent, which consent may be withheld in the Agent&#8217;s sole discretion):
$ ____ per share</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 10%">Comments:</TD>
                            <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 90%">&nbsp;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
    </TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 4%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 46%">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    </TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    </TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in"></P>

<!-- Field: Page; Sequence: 11; Options: NewSection Last; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>selb-20200806.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.4a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +K85w7xRiXgen8uNbXAsWaOOWbPtzp5xuekhuWh0bcl6Dy4vQi2OTSeK5e4GgbcA -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:selb="http://selectabio.com/20200806" elementFormDefault="qualified" targetNamespace="http://selectabio.com/20200806">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://selectabio.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="selb-20200806_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="selb-20200806_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>selb-20200806_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.4a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>selb-20200806_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.4a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://selectabio.com/role/Cover" xlink:href="selb-20200806.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://selectabio.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>tm2026355-3_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="selb-20200806.xsd" xlink:type="simple"/>
    <context id="From2020-08-06to2020-08-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
        </entity>
        <period>
            <startDate>2020-08-06</startDate>
            <endDate>2020-08-06</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2020-08-06to2020-08-06">0001453687</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2020-08-06to2020-08-06">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2020-08-06to2020-08-06">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2020-08-06to2020-08-06">2020-08-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2020-08-06to2020-08-06">SELECTA BIOSCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2020-08-06to2020-08-06">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2020-08-06to2020-08-06">001-37798</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2020-08-06to2020-08-06">26-1622110</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2020-08-06to2020-08-06">65 Grove Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2020-08-06to2020-08-06">Watertown</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2020-08-06to2020-08-06">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2020-08-06to2020-08-06">02472</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2020-08-06to2020-08-06">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2020-08-06to2020-08-06">923-1400</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2020-08-06to2020-08-06">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2020-08-06to2020-08-06">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2020-08-06to2020-08-06">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2020-08-06to2020-08-06">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2020-08-06to2020-08-06">Common stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2020-08-06to2020-08-06">SELB</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2020-08-06to2020-08-06">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2020-08-06to2020-08-06">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2020-08-06to2020-08-06">true</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140149781360952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 06, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  06,  2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SELECTA BIOSCIENCES, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001453687<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-1622110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">65 Grove Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Watertown<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">923-1400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SELB<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MI6J//X7W*+F?&^[_$L4/4$L#!!0    ( !V*!E&7BKL<P    !,"   +
M7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_
MK]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?2
M0$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-
MTG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z
M6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ '8H&4:K$(A8S 0
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M6N=6RKV'5[+E&''\GN4/4$L#!!0    ( !V*!E$D'INBK0   /@!   :
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=
M6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\
MI%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*<//Y#='7=:7PX_;(X
M\ \PO%WHJ45D*4H5&N1,PFBV-L%2XLM,EJ*H,AF**I9P6B#BR2!M:59]L$].
MM.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04    "  =B@9199!YDAD!  #/ P
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M<' N>&UL4$L! A0#%     @ '8H&48;L7V+O    *P(  !$
M ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ '8H&49E<G",0
M!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    "  =B@91_Y_QK&,$  #=$   &               @($."
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ '8H&48.II0/4
M 0  ,@8   T              ( !IPP  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M    "  =B@91EXJ[',     3 @  "P              @ &F#@  7W)E;',O
M+G)E;'-02P$"% ,4    "  =B@91JL0B%C,!   B @  #P
M@ &/#P  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ '8H&420>FZ*M
M^ $  !H              ( ![Q   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS4$L! A0#%     @ '8H&4660>9(9 0  SP,  !,              ( !
MU!$  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  'A,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2026355-3_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://selectabio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tm2026355-3_8k.htm">tm2026355-3_8k.htm</File>
    <File>selb-20200806.xsd</File>
    <File>selb-20200806_lab.xml</File>
    <File>selb-20200806_pre.xml</File>
    <File>tm2026355d3_ex1-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm2026355-3_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2026355-3_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "selb-20200806_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "selb-20200806_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "selb-20200806.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "selb",
   "nsuri": "http://selectabio.com/20200806",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2026355-3_8k.htm",
      "contextRef": "From2020-08-06to2020-08-06",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://selectabio.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2026355-3_8k.htm",
      "contextRef": "From2020-08-06to2020-08-06",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r9",
      "r11",
      "r12"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://selectabio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r10": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r11": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r12": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r13": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r14": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r15": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r16": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001104659-20-091529-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-20-091529-xbrl.zip
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M8@E90>),\DQNQYE9J:64A>J<9B=7=<T-]$G>;6V?@FY@A;_L@K(V--#'&N:
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M*E(1$_^!\CP'NT9VV<?JO';"0A*'?P!02P,$%     @ '8H&48?46&O]"@
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MG5LR )M-- Q10&S8G0%PE&*4JY&4>\3C3B0;+/:+).KI/-I"MX! 1IN$F*J
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MZN*BU>FTKB[C!+X><5\H'T#NZ-HP_RC7R)%BH5+>?1O<\QOQ6KB>HPX!O!+
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MJ#(4PQA0N$07N$2HB&E>5+L(1R"&,JYQ@5&0D?C^WKZ-[;_'@A>P^>9<OF*
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M6TC+QY/:G6>J]+S4(M;*5;(OR[D+-C!3G#,K!K8KZMDMZ\Y^NA/ 9/ITBF@
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MXF\M:B:.VD!=LOI![&,E_7G:ZB"A(R$P;X0 EG*3IA@\4V-_+@SPW OB0H!
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M"I&TF,LE)UI<6:8P6 6&0"=K%8RQPV^W)$K/T*12&]6B6FN9FS!C'$1=2Z0
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MNWMH?*4@W&%5<"L1R!+[\DR@:ZJ,?_6=#2+72;G;/CGN@44/'4-&:[$*\&B
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M9SGF!U+*<3-?>DS+.N'/T"+ RE#?EWQP:"O#_2SU,.& >!ANRK:LL^4'I]?
M=7(7[]CQCA7%C4#,_T;\80J]16>R#R1&S/Y902F;N@'Y+O%,]V'#Y&P^I#O=
M5@5LLH1QF&JRIYND.*.&_>ER/;78UZ@]DSV7]MBF'O%54^,$*:9,28:-VC.B
MV!166DJ;*^V+3'*01[Q'5YL0-I'+Q4A6J\SD0C]'30+C_GCQI866E,B2Y[PL
M2YC$BVK-<?'G9;U,,2&IZ#;,\_@!@29$@"<N"\?.W4L/&!?:P^1NEI\DC9Z*
M3\<SD6GB^-JW4K0+,;LRM2MX.FEA&<RXNC&(GA89&OK1N?0>LUY0A(%)SG#8
M1+<(3D>MN$!ZYL8]S9]H"O"X0TO)CRNM&@?7KZ-'VM4H$ +J@[!#E^GPJG\@
MT'"]*E$8SE*OR%YJ9ULZJH<2.=0B2;5F,0[HPW]$]<=2"W_YMS5(2Y22Y_IJ
M)6/@TL9&2%M45WK-IFT6-'5OL_6@ZF%$I J7Z9Q$W#REQH*5EY27Y%"&PWV&
M!VA[;L6+Y?$(#5A,L@;@<#;EU=PV1 Z898&-+6HADW0720H=HV4Y]RAOUY<J
M%.=="4PK\CFMDPXZ%[$W6\CU2\2Y1&E&R3@[<X\K.?LRA6CT>U';GWJ3@V64
MGBYN%'2Y)<2#YSJ>MMZH?6^$?<<1S!AI<"G7[9W]LZ/]4Y8WD>]Y;C<3SX](
MEN=XO#"7=Q^-H)WHNJ5JBZIY_CLIUB@IN<CG.Y_TC@?.+)QG?VC;8P@/Y98#
M&7W">>R0'E& U-$^T%4!77GH>8,-G6IKH!TN5>%KZ+5,8BX6"&R3O8?[)):?
MWX_^4B,3-/_?Z-&#_2AMHCK][;Y))PRA\GUF76@<6D)!R7[% E.V7V'M(UW
MM+J@S*O4%=Y0B39'**:8H&!C;7MFQ2NP0T0/_#V;?9@FLP\,2<>,Q-[CA^&,
MH_U'#Q\D][Z;[DTG$_/[Y^"KPO*!6(:CR'UX:,4>#:S8=P__:I;,;,%XQ _Q
MH'AB<=XRD 0'0B5/58;Z)>\VL[;KU5HG&Q,"NY4[5WG#-=K_OG<"#[__EI[Q
M\/OO_(YW7^.&9"H[?-TIK1R?TO'(,_V]1:)AJ>7'1Q^&7!(.]/77;Z,]<]J/
MWQX>!MJWLV9FY>;AZL-!IPU$P !U$W[KR"JWKGXBFR<-J\J"UW[P^_+UG\EH
MJ5*%IXQ'>^^S!L[^/__W^/C8I<]* M*XW"E6)/C%YF=D<WU&I(\X_N>V!_1=
M3^K#Z.XG")=ZG12^K9IB:)3<A%;: G T=RP"Y]C$^MZGL[.BS,M3QBX>@0-2
M+K%X$_T>L6?&(_DAW1B_=%J=L?_=7Q]^NH 19A)NNW:VJ1&X5T1O&4%*J=VB
M/@.7J/WV<./.KOA>HI! AGA127@_A8[5.';VPM#!"4VA@"B577772Q@.4EI+
MRUG;HQ.4\QI+/]>H\E8@S!+N5&N)O_':4^VR(09G&#O[TJAQFHR_FR?H1LD3
MEJ48KTFNF%W:5OZW(PY'(MD*\1 ?B6:CK!R5N'/EI%_=I5WF[H/-06Y/8)06
M$F7H)/XNZ4K,[0(XM]O7##A&$5;1?P@N0IGA3;^"..BOXYPI8:-Q7HQ#2 68
MI_$H #R1N>X]%H=@"!L04S92%LR0KU3:KT+:$GLOHM,60(6LLP7BR$).MV"?
ME(5..BU<<>708]YYZ2@3[I!6NV\\!B:BD*/.=:DC[/4IKZDCZH/37A:(S0C;
M'!$6@<@#N3< ]:MOFER97.;*$Z;@/T/]1Y8BU5\+B7(?JF]@M\'Z$+YD),L<
MS'1W6"1:@"9"5>^,:+J$^:\ON^,I;%QM&^D]A& B+6"]8FU 52O3A'Q0B>D[
M] "W4<0WD$#6R)H5A'"H3JMD25 GBAXXOQ<#2DF%7N=.%0U9;9%32;@768&N
M^:9SM^V1=@?4;;A6DFI)O6&JVL)B2JLAS16<VV\;79;%#BQ]Y!D0+SBBUJ<<
MQXL=S)L7'B8L)&-)KJQ U&]XMI8SCKJ9X!3:W,8T38TENXA7@8S8F!\H36_(
M(Z!V6)K0K-@$X'\EW3+[M@OB^<I)J%QY?+C>VP<8#8^/XL=!M;R+9UH:8:9>
M;T4XW>4"XPZ9.OA15&NO"Z^OE<M/E"4$;6C,&'WC)MO?)=[2N!O9_G9MS7.+
ML"+?WV%%[K BNT2F5JMKB$S9F-1FBC>.72K.4V&!:/2VRLZ3V68WRE51NR$L
MPKM*RH2(N0,0J&+:H^A:(P<^:EOB::6L0'-15A^HH4TUOZ!(5UTN&OZOBQ3>
MV73%/)$ZP*BQTK03Y/8^]3$L.;_(.M8<W75]$Q:HC:G=!,>"N<Q(2(Z&$T5&
M60QP P4\@Z3K'02SIZ0%S:,Z"/I9_('+"F*Z/Q6NE!R9?Z0PQ(UPNCZ%!4JK
MBN@NYBG*55SQ]U7Y*Q@C8++5N)X$_YN6RRE:DWC'I8"&#889EZHA-]&NFMTE
M^5KE6QC5[V??]]Q"L:OQBDV!EX0\DP78G' VZI"]E&O!M%= 9G(02'_*X)L6
M,Z(;O3.J8RT8HSY**]=."G85/+L$\R\T!HU R&+[<^5.8F2!IQAQ?4OP2Q@.
MW:YN7S$'JQZ@3%Q1,P5/KU.CV85'/ XF:(QRJ=X>C[8F?9[;'W-IN+\:$VYT
MUG^@L\JT0'#AA!;;$QSR"NT"_(9SX]#M6#?)*1O] ='KNG8 9>9\%7 *V#W.
MU&#"J[)V#>KU=0A,FV="2%%B],\< NJ7:'I:B>LU7[.?A0;:8F,2=HR7C5U*
M$IF;YF1XL9/OB*:J]#Q++QC]8VQO:H49,L/A+/KI].IV\9IDFYE8U\QB:_XI
MYU:+'&FF,C$U3[4K7!T[QV\P637L[>_D_I&3K'S.ME13.=:I;=\TUV7J\.>M
M6/-T;EKKEG4.+I] :1/G>](YT,"EOR?GKGT:8SF'(!:SVM/U:J+3Y#7OCT?^
M6@77O=OUC3I*NOYW?-3<52_HL-<-"/9&\8D8'\O3U1GZTL4:2=W@.MP#\9>[
M;XQ'\.<&G<T5MNCC8*E;0/X1G?KDHT-72D96GSA'0$/E!B+= MV?5Z#(*02F
M'\Q ,&8-^KD@U?7#*18Y&C%+GJ'V%I:+C0%P>8IF3>B*>=EL6V>#8L[I<M8J
MN%:RO!98R5!^]P1=<!^?UZS0^PHI;#Q?&:-6??Q7 \-O^0S!.>B)!&/5DI/@
M&PXB2WRV-4:2PCH:*_<WT4_"ABT6ESNR[TQ_1QMZ%<F4I9A!)+;B%@R5$*B,
M)6EML=Z"\,S=(@_KKW<>UIV'M8N']=MOU\S'$\!5WF6G9XTI;,=Z:NZ41,9M
M[N)^4FV6]!:<^49,LP2SP\2I5^;SM'(IB9I_#_]LX8-K3QPV0X*(JLF$F+Z4
M&!XQAI%%0?]&4[WF7#:1:YBG,7^ZV'3@-%2)Q*E*QG95-%L"PDM'JN[OO6 S
M(VNC,S54A'7K^$P*@<[(X>**T/[9MIE4+8S8VXVN? NF@.F6.YC,CE>EJJZY
M<,5>FV=5^:'=Z=(F<]M(D6(@P3)4DXQ1?S#JUQ38)UR\^@;CT4)^M\"E\@81
MEDW2J#PC+Y='4\6T!^1[TV(@%B#TL.*#(KG">:J8]ZQ&^)U,2]T43.4@Y[]%
MQ09U?GU"HJPT<-V/F+L[YSN>\[J^$3C\ZQ+#;#-"Q^#)\]VX?TZ*;"4FX($!
MR?,),M35/U^=<<N77/0DQ0PUJLVY!=P\PI(T7/GBZ9,<*0\Y =HQHR;2=\?N
M@WX4R?3AY!-K.:Y/ERP4XYQ;Z[8TZZ9S7U4F9>XCG5T-8TJFV5O/]95=M0P#
M"++2=DL&J.@#SQ^3]JVB.U,XAM5J7/2++T*W*R,V:,0T:)U0</ME/61PDOYY
MG=3SY+?HI[R<@CYD%L"P6$!@B';P;I1+E!1B@U0N8I1(& E?C\E1K[(M$;ME
M7C?/ONE>X7\<@=,T-ZA87QZ_?G?8:D"[ VF,Z1*DXL#5?=<4;N!_3]/F JVJ
M/?'JE\1!3Q>.WZS]: 8@ZWT#\7W-;/8_>O)?%)4BD$7E8QUL"3M$P12\;"8X
M@T%<%!VN=?>6=6%H^3&:WVRL3<J%GK0,,PGU"YJ%B^<9P[)HY.[O?_\ [M8<
M"T^7&)>$,>8$%0+OW=6LSE7:#&#:+\A(R1J.E7,NUUD1EG)]QZ*,[<V@[N[G
MCO=SO;X)?/C1N^.3P_&HK\7[@JLJ&FKC84)CG]V<]A* =LQ9?9'^CA&(KQ38
MXWGB FV74%<_VGODNR7J<]ZEC923(V(6[.8T@'<*&^+CD!XMK/JVT6O* JVU
M"PV%H>&Z-4F; VT\,DA;6O4PZQ%T+VF+*)9G6EPCSWGN^9%^JLKURBV*JD)J
MA+P)V3)=SB<Q#TTLU](I/HN\6D& .4Z/X85^O/_8"[BY142/1^U<0RS'B$Z!
MSXT0ZTY NO,6-CI (V?UCM3XINK )S5,TD)S%9=7(D:T4Z:D9YY*\+A-ED;#
MQR$;Q-1XQ(#BX__%U>%'[243TXB&X3LTJ/3<<K*'%HU;YP>/'[E'$2UL5,[$
MG0P.D&/7ZC]![:-CMR1P2P6&.YUL=76#A[O>J?[I@=M+\1W>)BJO@H_-,6 [
MMF?92GE[4G!(2#F/^)JQ+8'+3ZX&[/HR6R]KK(6WV-^W4B_V3&3)3^L$PT=8
M$^S.>AS@BE2PE=B.%&'MF*:J.72FY1"P40EX"!-LW$I1?-A?.@FN][L!T?DK
M\]!>&5P6)[8>//03Q[7#BA@6G34,L69"APAK"9?KI?(B40JNF&-#F?[+RDCT
M5*ESPG?3RTPK2G^<?9*X87 BU^5P@@0SGR+>_!G=QS-NGX\K4)I?,%TB\PS;
M,^PYD*;.F^. @JD)2E!#&'VT#4#(/AR. ZP37\LK(Y$<VNW)1^P_N$M(W"4D
M=C$VS\]O)/IT0@%X%Z%XQ6UK \!7*P80-"WS@5A7V/(0=5-/XQ&&(6!1"/X<
MRWJ' Q3=VGE/R^U872W7,W/ON=:JI#8IQ"H-@;&MME8JL\F(0LHX6]X9--/M
M#^$P%CR7!K_=7[E2\_Z9%4IW::<7U+83"D53MK8M@L:3)1S<']JQ46 :H)FW
M )2M)TCK5G^!+JM_'+_OXN(:KJ*Y@BGBLI+QZ-TO)WSQY)-H#SZ9P)WDPL57
MSB1S),E@V<S+E&DEL&DD?HC4[83T0HC-VQ[J':VP=T:Z5AVT(R$.F>AB->YE
MSBXUE-Q##^Y$6#SBD0B9[WJX7>GT??QX@U%!?!>(T)=9WM8"7@KS5Z@#%/IZ
MBXQ))RW%VY2[%@[%P.^V>K>MWFQN1.>_(8/^%V4T1<7@4HT]W7Z5MB8H1_-U
M8DHNRNE/QG(ZKM1(<Z@"!= $ JLTSF68#J\&>"N15Y/@N&7'YA 1F*XQ9AJQ
MK3,>21&>ZQB*N2F)J212)C<04^]B3'W:F>^M3SX)0VR=YJZUK+(Y=I/92>$1
M+!B#8CNH/D/Q,$4J%X3D1DDP4,EZ"UQDTRJ1#0>3N'B"1#\Q=2B#UBRW*792
MI]*LWBT[.Y\H<@XB^FZ=_3OE\?WIZ7L;N=J6K:32VT6'QP,K'K)"0T)T&/2\
M6>_!6D,2M-@K)T2$PF1*,;5GH//8(3.<1ZT_'3)UO1!$([GW2LX'%\<)KKBI
MULW98IW;Z@O7;:AU6*7]K9PVJ:GUE(G4G R._U=XSJ9E/O_DU[LW?98B0[YV
MWM;QZ-%]C"#+?D?')R>_'+Y^?A0=OGX1G1R^.HK>O(R>O_GYYS>OHY._';X[
M.KGY:?WNKBE8!LD7Z./+< ??890M@S=\D;BUIV/F"ZZ* P&JCC$UY7B!6(-H
MK2\2"THTUG&B2OMVKA?@,G+W4W!B\)8V9W%'#!AIA&^,.BT%$5+![CGF:O%E
M^+]UFGZ@FYQB?D*T5W-6E>O3,RM/I(\9=@9.*$G!'[MJ]'S3$D#^!Z[G-R6Q
M%B4AM&-C.DF2+L)E!UGS5N$JZY7K^Y)\I.#R6RDE/UPB?C[VC16ESVJ;!?)8
M-?-KH<I+ZLZ:B%".H_FZHL"U3F*&K#%55MXZ-.0NL=O]N]CMEX[=[G1.S)!.
M5GG6W#M)J>[I('J=+'$Y'O(@;\E1_F0E,_U$)>/42(0MW5)T_+,9*0N51:Q+
M_@ BA?\O/OK+='&=@ N]2W#QEZ<ML<_*^Q>U@[V"-8E0@1BKOG6*5C1OS$IF
M0Z53J-=>H.98.RK00%]0>-^C)WH?"\JJ:_<_ =N&['X<7/#YE#]GM]+C]CD!
MFVG+/ >M)/@DERVDY/JZD@&,5*5U,^"V3ITZ-.6(ZN.TM>E!]./Q4^*!(U#*
M67F1P@]__.;X:8Q*%,R/O4-J85.4#"<@=6O5K[RKY]GZ;CA!U$> GG;,@+D:
M# $8\M['20CR8?N! <4.W2KS!2O!O4&-AU6^KJ.]S9:G:'FS0EZI\Y\$]O#S
M%5:^8L"F8V=P[@5#%ML ^XQS0.":-,3MMW,D$?YL@J84!B3* #!/@>]P 'P<
M5G(:_:G3B-30P.T!2S^N,D%(T%G37 I2.1UV-\Q%/- _A!.!/W7^KDMXV>O#
MJ7S*VK@4$!S ]"__]_&3 RKLU'I8:1];E[XI!IE[&L&3^(ESQKD@O%HZWAKO
MQN._71VI+5&/SDN8!KT6Q$Z-VGS;ZR>Q1R'2@2"X@S)\J76KE JT;^-12&)F
M^H30S:!26IX)9J5<*$??WS'>KT^)?)(H_QK4R=5Z>X-(E4#>T0(O1/U9FH$P
M+>&%=K$6.M"KAJ]GYW9Z'T/ZIJQ%3 _Q0J0\7+Y;=>,BS_B; @M@<W7+*+3#
M=VSEVBIC]1G8V*F!R OPW4#&O,+B@6&^@US)N>!<.LZ?7Z1XR '#Q]D:77P;
MW1^,I?(%Z(BN=9%C4,I7( 1U!Y[+O1&GV)&7.<:R&!M@SU+"?-GF9$:&42RW
M;[1\!CH\O+Z160*"8JYZ<UZNI]+PATC1TKHKY^WE-H<!NUV2Y+00:E6G^$00
M5B4*$7+GC;33%I H&X+R^SMQ0("W*\F#G]/FC"RV!7;*E.; : +X7) </-S%
MJ?1$%-18C7$X-7+24]A.Y@WMM)\3&5(+GWXK10&:W:<V*#^UI%&AY!?RMRDV
M0;[0; )'D^$L;4TI:?/&5CG*&J[4XWTT-?<>3WR6DB!S"O0G/@##(YPC4,9.
M*Q9)0)E.7P55")Q> CZ*RQ!&4?DZU=GZN:8?&8)!;?OH=5+FTP=+P4(O1NIU
MI&\GYR+6+A;("EK4)_$X1"9Y%5YL[%M8NB- DL=)*\5=^M(%W$H,A0@]@2\^
M"'XSRPGRAT<DF9;GZ21\(4ME[;) EKLWQ+TD=A.S20>'*,!JARJ]$P B *X"
M%2-&>K(4!1 4IE=8!!PO^H.?D0/36T..U+E(<=./P[^DG<(!YRA/&@$3LV%0
M@A8S75>MS5S G"6$JJZG_;/S.S/6WW2^YBK!? =TI$'%W[ A@T]A*A*2@U))
M3L)-FVZ9E\0BS;3%"'YL?28-1CN]SA^WL,\NP5YX&X2S77>G>+<([$'TAGD'
M?L"A:*C@+BI[<U'9W^]Y^G3D[=6DZ8FC5Y:&[D<)E1QT DTD)J>I\#'/U7(P
M53'^44@.Q,P;)(IZGD;Y]]!E(T9R[5  W^P)MN$08RE:Y'/)=0:M-X>I-APX
MEW+C#!C1CUZ8]@1DW8":)(X(R5B5Q'6<;_Q7C#?#+<Y(U&)JG=BD;$RQ4:)H
MP?NF3NTKAQ38!&BDODA799UQZZ+W%1P&T]>-DWGX%/G6-_\ >VA>)1=(. O?
M1&JJ.;+H[[WXQ^'SB;"$Q5+M0*NN=FG"R^GB3XD:QN/1<MUP 9YXC>0,BR&C
MSA&*>++^YN(L&T>96RC2NO@.IMP(@U@MG1F$A(]2@(U')9:&S["T]$^+TJY=
ML?HI]KZ282N5R[*CN5TRD!AFJM1O&F*(?!6K[V,^'F'%2QV+V\_T$RW=AYE;
M;+>*I;#T[1!YE!1N-WF;D\8S+NLVNM ?G1YW1,<C/*,A: TW!/.Y>LC:>"*7
MD"774^@![*;!QW038#KI.<4NT3<U.'@\L-M"FWU=Z]]GW%^;G2M?2/?%]/WO
M7A9?T;4]<=3DA'1_[[N5Z39(_.MY*ZKD*K?$$3.D^2ZF%$I%BY+#XR>7N]!8
MOMBUQ@D306#"&L+5XH.S/HAK+QY\AYHG9QP8PX#M1&G8N81 @T8J2HCEW,?#
MPPA>3^J!Y8Q]IPL;;4EY1"[CP95MOAT<O]^L/K^ <*52HE$A6VR258&CZFO_
M#5=D.VI'O0+Y8HJQCWH2]8FW]B7Z+&*@+7$+2>9@?B$+8Q.RJ@16=VM0]RRR
M*?KG,R![5\MB)"@GVSU_@S?1DG /4 RR\(RE; Y+;#<\\ZX:?[0WG8"90NFQ
M]N(8C7+ &+:]YYU)2KTD*0G4D7ZU3:+%$(LDVPT$DJ.U2VZ05CDC<6E#J]62
M8IS):9(5-<?_L"8PUK8<\V2)EJM4IR(%Y=XEG:]6VN HYK)O3O*9;F2P WEZ
M"D)_D4J@6!Y=3PB8HR6QV-.#>L4@1:TPT?;@7FEM9>TZ/5[>]ZA\CY_DK? P
M):IQ%8)I"NTTX9G7&%48:P^3)^"\5.5%7S42TZSE*25I)) S'G%"L@.20J<9
M+Z;7SUZ'LAC4$$#8&X%Z _#J$%4E!GMBH7W>1%KVZ9Y%.;F&V76(JH+6FI:4
M)X)5!2VB7'.NM(=+T4J]<=81<=!ZL/PB252=\VT8AW,74O-+.^36 MAJZPYF
MD^L%-OQNO2U0U%?4U*_A0$CQ=TI2]:W&!>/HJ)GU-$6T8&1WF6JO@RB6@ED0
M/!98-5AK,[86=%D<,6P#0BR_BW5.MQ$&0($=YV"1?FC]CLOE,8)E2:5# =HR
M$WS<EPF"41K#F<3B*FY59PQ7B:T^E\7L"8BR9( !A.]T5(M6:GNKE_&;6Q+S
MV*)#X[D^>221W9GU<3J99RL&[ZX"7H6K)F0<#\OKLKCW%KE,9I9WF"\#F&JH
MA5S2W7 #J]O?UTOSJJ!9(A$56\V#53IPBS;T-7BR?T+;L.&<K+?@%(+*$ T!
M;V1%#Q$+<X]X1GR<JZL\+&#=5KQN6;!N?Z#3^$4<KMF- \U?INJ#'5+R'^TQ
MEF(4[M(NVQ49+RV4EQRL5=)&7E\:2Q/\P0E(6CQMIKA:RYW,;UNP*8N9Z?-%
M@JYA/MW._H**7#(].C9\-F$K/I"I\*3US(7$^H:L%>?#8_XC@"VO.7OP\"Y1
M\#7"M_G__7U(Q_F-2,?(P*>/Q#^57$*?-U22_*,8<5E3M[FV<^NIG@:8B,7Q
MU)1"R_G$GJX:1Q&,4]]#+F,BMFB*KO>.9 8\?9R)CAQU/W=<40$?4*6'G,G.
MU@W;[I#5R\EK7)/BM$K.\5^T6N#W>_P<E;/+XG&+NL(4,BIO1J4(,Y/L" <0
M1P:$0Y9/BGX%DE41?C8VOW;ME<".6ZZP+P?M%Y'C=I;X$I[X./*Y?SN7J#V5
M-B.#U$]2UY9Y2LJ+/%TRH- _YTK:=*Z?2:R>B-[]%)(YF)U$&[QGAT$+O<N!
M%$">H$Q6B=)_Z0;&0C801]@M>*5;:IO^Z@P'F#3-R5B 5BZ8#[1V?<F10O,L
MFV;X7_7L#!1OCLOJZCT)6.O+BFE!<5(5G20&_BB/)E,@OT2;^A\22/!_1#XY
MTSN$NS_QI-FE0B<2/5<P<!;$7[/F#JPQ5WS#V5&NA2#NY)M1VB:680M),GTP
M(*5F>N@@^""[IW>@HP1?!T53%>G&]7K;(FI:N9M2$%9LTO2($.GO(F%PS5_A
M/_?(H<9Z0?Q7^A'D"@L99_<$]&'^YX[;9\*]JBN,NFTH*M>2&&CTM8!/GKN"
MCD?0EZ"*IOD:/OJPT79+<FC![RILRQW\-G]C@8V*BV2>2)=B\/D]+M^:>[$<
M SW=7GII(ND9OOL$WGVRKL[3C>%/6*;+$B3+?+WD8^ (%^C5F-V\J,!&3*O8
MM:+1A('I,.I/!][G5BJVC["MCH,%QRY$\]1$^_6(Z,;1&1/J7X/P=8=).Z<*
MQ!#N]Q0I_J3_Z:(' &8%F%QP'S QKV@]O5= ]O(>])S86)B,N?47[B@=+[F!
MV"3JG)N#=X?;:1Y,J2$'5AR0:4[(4T2!/C*W,U25[:%%-+*][*,))/7(Y18P
MTW;EXKYF3.7H:WVE)L@=M*I,,.-<7@2=EYBY:\!N<%W:'6. +D1KWMWH_WAD
MP_]N%LI$;6F2C4*1YNUPH$PN$*?KP0J1F\?P8UV/,?+.^"GN9U$-;H <+FK&
ME<UZ+3/7:JU 2GO2I\SY/FAFX2LP)@/O"'?"3!73Y.T3Z'-.8/_ \<9AY.7\
ME&5JV]2QC"*H%5V;;#*-?%> ;L]*>^"->$$^#C])'R#BGGR\"DE6S:IDT40S
MV'$&+W07@9?=+S3%1^VQ[BYR^SQ8[K;+V?(Y!^'MPHXXZA5%06S5IT9J4J\J
M +FM%][FF/,E)E(F)5$8R?[SDP?Q@P</>LU"WT2D$^MS(>L_[S^1WW=.%&$<
MWE?9Z2E?N:-SAS;JMJ=L%?692)PE?U+D9Q+0U_1Q!2+'QU<8F/C*&#,>!XP9
MAR]>'+\_?O/Z\%7T_,W_'KT^?/W^#\V183U>)/TI$K)@3<+'R3T'[G'\"@AN
MF'/5D@;GM)>M/*G-3T'H_#2OTPO*'G40]C]\?<?UZPR-W Q#B>7)%T8Y<"EF
MC>F.P['D%P-UR7WA8Z11Q*8*7."L!'>4(3,5CB;>FA"O$/*$RTE4D[+#@L>]
M&MB5< RIC^((V=FK:/])+U&J$D4G12$.B:&/YA(IF@LUE_7Y]\YS'&VC(&JX
M2@=MJ%2!'F#&HZ*E2CN:#R[!2VQRO?_@WO]$VID61K).\O9WQB/XTM\1X49=
MJ2K$D8"7QAZZ6L\./\<_IJ(\V8F]_8G!W5OF,)1;'0(6JT+0".BJNH?RO+3A
MCM'I/"RKM5O/N A%YM12@Z0N..5*G:_NG2/2O^*)QHP*<>MI,*)BE@>U2QR[
MM^5%Q/)M-TP8]PO;K1QQ+-D2&6'<<% =G+@A*88P5M 5;T6KQ37Z[E$.CA"\
ME0)(NO7=4D]85Y^7 /7#&&$\R=)"EX=D@QE^-(&>YSJKAX^1$=B[TZU%V-OY
M@-O'X8_XWX\>/!M\^.2FS8NOB4O\T5T^XXY*_"9Y77;/Z;:N>%LY'SJDI/(U
M;@,I2(X7Y/6*NH9@4"H-(S,"U,)N#Q/OPYKR\PV7E;/#)B%4"KYQZ$^-1&YH
M[L5]D@=R%'5&W#(&.'\@+P6UA-*+3 *9&3>0S"6<0>%'\'CO&9B:QFDUP]$?
MNN9H,HN\;XECO?][KK&??VXP)==X8[<XM:0R7+?)8'K,^-R9$MA$N\U)P5"7
MSPIL*>P+5%MXGS;&D*&YW,ATX[C5'6&Z]/T#41.1H-,<O=J([K&6"W+[H(>W
M4<*G'&S>86Y7W3#*#?",>#)(99(6BB#W4^-UH*:)BZW)"+'5[+;[=X@I123/
M5$^\)&"GPLTMQH&M*@VO8+S]MW4I^3W=DA8TU?1C1'&AC8<9/.]B#1O3.8!-
M2RG&]";8G'GY7>T(?LN]/:9KH8?XC'K%%>[WV%G-Q@'MC!V!L3*1"+TI%<6V
MCAE+*@PM5S[JY0\=' A/<] MJ7(,&"9>/44(LS)?8&MF2H/03_-LH4%3MCSI
M*&!];HDF7ZUU"O@<$+E.PN6;..P]T$)K\R0LX-RE-EPEV8 E]HA;=#D02CQH
MF+';-#1K,V$!T7M1HW3CY*BW;'HI[,75L".$'=0!<N<^]0F8 ,,SFI._Y9\I
MV_H51JB^3KOBYK%BAV%.\\0FK3I2$K_!5.<M<R1HK7<LH?]SCU.DYD="1\ZW
M!L$ 2$>$IUN[S\(U<'7F2)'N4OP8:%J*9+1B/!Q=77JDI?G8=5A0QQ*\P771
M5.O4I*FY0YP#.RX2]B5+<#8IVDSYRO87# :A$&$!WUTF'U*?Y#3Y/Z2F<9(&
MB=,P@TD!^ZR:K9>(.D58WL596K3GD+5K^QP8N8II;G"QP!6=.Q]ZX5)@S!4=
MYA \%3FWY#:6'ZV\1R=?=0]:A34&/9<G%^T6@_X04<2IM^)EK]M6C _QX[TY
M2TH?^EY,)A(M9[M6(@_B:?>&G>#WBW559/49J1*"Z5P4KCRFA<#U=R58A+ZK
M8@^C.0A99VM)O6@31M*I_L&I"/3>TQO=P.%%CK_=3V]T#8<7^UJXLTOV3?\U
MMJTJH]8B"2_Y\,$;/'?</_JU:?L79)ZXGS9;C+$V*1)T5.SMD2$S4_6^MN2&
MF5\DA/966W.@*Z\%BH613CKU914<^CMM^E5@"Y4&SA^>=X05H,J;JEQ1Z^!A
M=1L$V3U4/W)(_9Z:4JPW8;\D=I7<H%C9@Y+'7.(#78[J8M2"^9:7.R86#[,%
M@U!$,_MF@R'$KG-$5$?F?8.#5M:!PC1N)3W*H\1X>) A:$?P)V+VTA+5'ALQ
M /]#H1/@+LF4[016/!$D7WE1*6&)_()")(P>20($#4/@\<5,UF9*\E=Z<!JI
M<]? 1X56OL#.2!C!.%<D42CBS8Z5_GA@.1DR,*@<3039B%-'_VD9J78*2XL?
MJ%O>F]<)4_SB==RBB//CNXCS7<1Y%UV6WKAG^ L'N08"7*RN7@\T3/92C_C"
M!(3+B-LXP-HR<(R!>? W,H"%[4R,=_B-_*3S?5^S3H*\Z9(<L# UC&FU"_Q*
M1M#_;;E<%P*_E P@+(?=(-I!$F\@@]-[=;/)X28@66>>_NDI*A:%E'B;K_8@
M4R28<0707A ZW*C0&@A=;)4J5(AB*BQA'SR)KC B^H,.J4<@7^%1#!,S55D!
MJG"[BM01[#F#>6 EA+?('@\A8T7;WP$B?WSV=/!0W@0!S!_<*E[<B"3IJ4KL
MW[.TIS_>-5I1#E*ZQ8R*AJPH][.A WM9GH'S%E28.$VC:RA&:%>#&W0CXVTH
M-5%Y>2E&%TUC//J\>032M@W1),FZ?1L-68F7W A,/4UCIORBK.(J\RC>H0%O
M74K>U38^!5]AZ5*00L-T59?L)8<O#7<R130"[$H6DG3T 3"VLZJ$'%?>;]K_
M[A'XJ)-.6[<^GA1&V(0U6MCW*2M,\#4+IZ+>$V%NPY!(?]98&1^T=STM-?XW
M>J_R#HJ*G*=YN5H*5K ;S]VRD\BH]_FW G,:X* T/$1N@*"?]5.&NW99I%VW
MYR9M.HR?_6G!N&!X070._-=KCRWW1.<PJ\EH,B;]31K&4:/WT7"FO1M.W@8<
MZ D(;U7P,(44+P)E-BD*72'),_V(@FV\8T0V-10_W?J"()K:CA/N%$PELMK_
M0"J@NUUT-<Q^"1A-]ROJWR[I18;DAL*A>"F]F(LXT+JYG+<N'*6]+[/=^L[)
M]8=!! VRBP+OB8#TG(C!<S2D9D&'#NI9'PR^PILNUZEWANQNANSIS1-K.-01
MG^4KF[1X6;%RBZVMF: XX JR3A"]*9)!<W4AMD!])!\\&PS@=8&CC]# V!*A
M^R0M;0;;HH'R>42>G^MS3XTU.G-H7%'\;3OS.T0&G]Q%!K]&;HW?AV@\N^G,
MUW/RVLAV&K"C4:.VPX>7H58C6[&0(])>_!AA&#8N6;=PXVH^64=87L$E$Y*%
M'I^LG\2S]):1$Y7T!/%]]]AKDM8PIH26_^ZAL5N6FNL>.@A*5_MB_.P>D$_K
MUP-1#=%3Z%3Y-"4C2#B;<YE2ZMDF099)(G$XHR2($>IEI$[!;_A<?I18P=L\
M_6[GLP/'(T!'TC;#&SQL@[H4+5/W-\=M0/Q;;1X#L@9^A0_K><8V@?7:N;K:
MFL-@C6]GM#?IX\MHB0=*HGW!>&73HJZ3#)4Q+9Q7(B!FC3M@T-_%#'HC ET0
M3$-QEB''#<T'C5E\!@:&:,P_R6^35.MN?C9OO(':$D:2\)443J(U&T#(].&Y
MD(1AX7&SE.?@ ]V!R@G7GY1AN;J?'>%;?,3(&#,MG%HE<!M7G&?R\"QWR1U"
M>Z4'Z&07N(V%[=Z=SHMC_!U2TRXZY)B^_VC+_G2 :CS-M38D=_$RO>VU/-AU
M/)5V?H+?2=&59D P/Z<?$3PYT%MA9?X\G1%KP9;UWU)U<+5K0DO4*>9PT9J0
M!UV4@&DAY*L^)@PF)BR=%.\A2P^UI0BR]?KH?FS=)V)/U..Y@GQ@'XI!8#ZB
M9*4#B0(I7:BD.$$Y%+24)@R4C$?=2 EL[N %\QC*$-O@&#X#'>(;%*$$L3Q?
MRB7=9T&TXF]V=P:]0(Y*#&[&'P)<<?U=H6\N)]8-*SCVH7955S> ,"M+.&^H
MR]HU^M2?MH]F!XZ@$$%9%B@AZ_1<38:AR;-#]5)#B?'AB*"<HKR,T,E1)GE6
M)Z0L[YA#8)R#H+$&4=W3PD3R2-WB"CKP]"P"=2D($P3;.NVE6D)SSG MM:B5
M\$*JO"BCO.26;>Z&ZV(/TPL-!8*FJ7L*90AUE\A@0E\:)AP%.#<V (?C1XJ5
M9IL'U@>.2JZ$K]09$,MPZEJS1+08=IW!DV&2!K8JRD8)<6!M9=$DAZ%?XQ=C
MSR53\)Q\E"KI@9F$*T)RF]66S<\Y*2>+:7I?R">7<93107;S=#MJ.9@F47@-
MI%DC,^(E3*6OA5&R:(&A+B^P!4]X'+ :JEOZY"PX6_;DFMSB0,A\=EW&;4\J
M7YIFZNRZASENK4'EI]VG2;12J%44!2/P55$7OJN3A-F'2J)N6=#ND[7+KU]4
MNQPE54'U7<["<MS0/9O84T1'WI ($]NCBBC,FEJE_H8:DI!]7,Q=&PC53E&J
MP_!&F<0Y"B1E$H&8K.<9R/@)T<DP%%H-K'+A"1>:BS0_!R-V_^$D6L+2G^$1
MAETLE F5!0G8MNCG9_4,#J^R,[0[Y9*?2F^Z+!K%PY6F,G#!:G%%PDH^1_.P
MO[^7N%K:#A962OSVGWP_&$.XNU [7J@/-Y[Y><4%N ?@LZ Z=1J&-0=?*-SM
MCEY;@A@U!::U9>4+B=(Z_8WI&F'\JW,C*QH$V_T?TG1E[B1&CN ;#2\0I7-(
M[Z>D!> W%88M<.V\Z4=GF+4109\P3"; $(]L1^=9SGR[DXX-Z<%-+]>-ZZ#0
M#C?U-=VY;<=\AV3/MW?)GEN?[/D=DK?G7\ZP04*E]TKY34;&D,O,Y)\1=\UB
M84S432C%I,Z3D2A;N,A52HI#=\L$UB>?A^6UG0>KBU^ &_\B@X&G?=QT")^_
MC/]&E*C+"+6B*EQ+YH!)\S5Z]_(^C!5051]6LJ]G[7C$-3#Y#Z0G*2Q)4*P6
M#QG:YV2^.AO <^=1 "0M,H;:<: ^4JI9UQBHP,?ET71=9T36 B^OA,8QZ%OD
M*QM]URM^6!U_6L;M[B;M>).*&[=PWZ4A]S%N_S^2"KO'97V IJ!9',6@*&D<
M9$V[Z4:77-;O4;!C2QM,WY5MCC=9JP7WB.H7ZSA=^B)P.%TBJ.J9UH6;EJ-@
M,$!BA@5SNHIS=ELZ$B?4S'DM"1+)/20NK:Z.)+/\M=:"Z7,8^MII_MF%<<IG
MA(>@825"!EV'59]S^KUO-2<P@CEXP3EA(;NI.8^-8*"G%R##";Y&2W.&Z>XG
ML2/,Y/-&>5LF+V=QW>J3B7(91M"A(W/5\C3!2[;4@7RG6[>F+V_N53R*>4_4
MWK=]5]D.*F_&[1#(]>63H%,_'@7'GMN 7Y(\4^!JF#S3O%G8MB*=1YU9\O3O
MJJ=V%<SEC0OF%[Z[?(V'K)=:'%RPYZ:)2D]O3T-)U464F(B71,W&HQ[1[2R&
M84.K-XJFD;C.%4)*LMO"_[Q/K2L/KW!>*/[BF0Y[L!IGZ6".77(&PU4M5OXS
MI 0.1ZO4R=+T.E%1ESFU+^=@C^DL8=-__H$VTM7*@G=K_DW[OL=[R015Q]XS
M:N WB4$<;J)EFG"8-1FD"XRQX_?L0UJUV0ZP/HH4@WE,FTG"Z+X6GD7KUW99
MT1OG$OB/G=]GGWA^^Y );"(&3-B6+/OO?%[:A-HAGW:+J,3]]IM#_+7CU/X?
M^+?GF7;ZT'6L"FK#Z+4.)]9AWL2JG*Q<U_E&#O#V&;CQXQ7J3&!">#(R%]#6
MBUOI">Q!]$<X2[N%/;^["WO>"O8+%B7/KUF41 0X=;SX[II]C_<P3/KM+ I8
M,Z+@3XK@#\KIP$#N=*XL#E:9'8-JB![>?_ 0Q<!W]Q_L$Y^&&U)E6[N(>[:N
MTLXCQJ/OV[^U9COX-7D"J^"!$ MJ$X-))ZQ_0[.0$='X#L'!S"..>"G !;L/
M5G.RS6AY3X)RR)=N;0ZY2R&^^@1S/$DUAX-1WH_V'S\6;J6L]K*S3131,A+"
M3;%E3S[49 -Q,'[P*VE?/*SCG'1[8AC^>RUDRPVQM5C1XS^UH-HYXKBR.:$@
MX?!*>Z&R #V0V2(H$_C2GFUJ>1.JHZ\*V6'8Y0QW=$7/(38+/9' 9= ?R/NZ
MO0OB@,R$WY>>!8Q@'H\XU9?,FK(*&T%'VL!"^\/IKYJ,T %U!GY3XOP*>K91
MF(JN['TF5@#+0Y?E7/"XB4$WQ]?D!G=PLV"6<_EQAKME(A.7AH_ZQ(K&6"Z-
M%,74( -?%D:AB#2'&\BFW'JR[+20C7P'66&7<#_8XM_Q&?.') Z) # #W.+E
M\H\=L-.?@)U.[J:KP<68S_-)(&1]FR#W;L)(M ';9TD8F7>L#._/W,C4%NOO
MBF4RS($S4?(@-9PX'B5K4-$)PE[PW!(QHU2L%%2@0\--7!\Z/TA$,FK+$P%T
M];?[,M"21DB1&?]?E%WWVG/YL?UIX&Z9P2#&2JF@HU=*R1;.$85T[K?>G"[L
M)$D1!7PJ7)VU9"4T *;E'N*S^6,F<!T"B](Q@B^B!G#(&A>JQ<KEC'K+PT3\
MVHQ'?G$F]W'BN-P.*R#R(CTM*0O2 M+[PO<\0-5;1#]WJ6+44'M+QB/:$Z'S
M,*M[D5B()W>*G OVD0^8W_H>*;O]O)&F*3"0AS-K50;(+K!2N'PG E0O3KNF
MLR=_;3/GX<7VSQR D5\^/<YGH01 A)>87@-W:TY1XL1'U7U+@UWGB%*2&CK/
M[W#I/='&U<T#G=)3L-O>,&NTQ!'?[! O[,WTM!11JS.B%0=\L@R_6&]/1%%_
M[;J*H::(?6=T46IA%@IAD9V9I=@7^/?E[#A]=RJHD5'?((Z<-<%Y4*M.L*D%
M6#BHU3&(!:M8<1%9GC;:3(I@N,)3E],&&5KO5PG<L&7TEV2Y.HC^D30?X)Y%
MKUZ]C5T]@.R9XT'"Q!,K8R4!-QIWT/*++Q_*/\I\$?T$RP.&%#BP:&$V(*?0
M_DIR=48VG3H%&=BGMW8\^>7MT\<_?H/_(R<95I73C'Q:S!YJXI',WZ[I&^VR
M%#L:P0X$>R4K.+I.(_BJE527<L5TC_PT-!G5CP(C:@DJ3UQG+#D+CPO.MGOL
M]=1[JP..# L.V_)G]Z!A;]"M-4LQ]CYCEI&;)-<)RAP1[X!Z>-LE\#.5^H(.
MMED T/>C8[AR6;KV_4E$2HM)YHB!^/M@&DIGC]B5:AL/.I!!P80Q8:SS0UP4
M5R3ISO@N?RWQHJW6N4.?;179T$6H,&E0<H+!W01?4:]KQJ_QAU_ZG\"R55E0
MWPQG!J-CRA<$'P\TW>7<J_@:/5Q2K)_T_3UX@VOQ.,&GMHE7=L[I_;W#OG49
MV!W"P]_?A8=O/2KVDTWGWVZ> F6)]5/CT2N28(R8NB'3.71I;\!TMG;S@$$L
M96J[6<1'%3A_8J/^"_3&*5NH[!;.4XQ\<.B4JU,IV@0CGE%@6@+.U+7JXJS$
M\!B&;ZA22)91X].!>/>LC9?R% QU".SE:DDP5DB;[;35%[(S48E<5[15'WH0
M=>P]L8)<C'VF1UML ()84>#;FD52Q]*OA7V[ !D+7&X'U,L:#1;6_7M)>5:A
MV6EE?OK[/$A1I=EUXBDU",)M1X*:U'A%CIRP3/F2UMT"Y.Z13_*ZE'.?1.%)
M:;N&X<YHQP6PS_?V'TQ@*1,&Y;T ==+&% K!BJD/]6D7CS:F$M!SOENX3R[0
MYJWI+7DSVYRYE1$?SIX'<;MVSR>04Y:RQ7S3\1ZZQYK^7+U%U+O:Y*TMV,VW
MZ',<=D$D_('C5GO5%70H!U_ V0"7U6?S#$CMTQ7D3NF[EG)+/Z8S[#! ("+&
M?\K@.@<6B0:DWEOBW*MDEC6;;5*> ,G\OHU+("5- X>+?T'\V0GYPSX)M 1_
MH$E;5%QP0\I\+:P':VK/6ZZ,V'E6)A55P[[(,(=45ITT5+)NSLHJ^[=KQ4IS
M%Z?;A?\W?> ]<6(P@(]=S^V%OJR$X5*&-5+VLI.NQKTG>MWBH#89#YH5#\I)
M -2NZYR"28HOYTB^Q!CZP=@@V$P2C!L.F^WCVH<FK37)+EEL.GPPS?5R"H(7
M3\3_;^]:F^)&LNQW(O@/"L?T!L3*;HS==D][UA%EP#W,V. UN'L[)B8F1)4*
MU%9)-5(5-//K-^\K\V9*J@<4&&SZ@]N&*BG?>1_GG@-S20V;$#D[7G0C('E"
MOHIIE3I \(>TJE&#%52:>$$NH\( (R/U3V[2P"-NH^34E/$D.>P.<\)YMZ3D
MHD4S<M^6>[I1+W?T!2"&PXM"H!.OHIT\@QN-?RL_;U98,/]O[=L(S$814V9&
M^&*ZY!:MM03)UJ#DUV<;!ME#-K:)3TCPI?PSSD#WJ?$2T48&)&)_JUM)Z4GY
M4[8W1T2_X>K?C<ER"VF_.#>[C9 X[^QA.HM?.,-ON"@_\N\R2;:0D=16L#=D
MTL?P'K(Z-,30,(I(;%*B[&LF79B+T0[S'E5:F6=\GG%<LD&65%G*HM?DZF&4
MK.!6XWG6][2'X8EZ$.3IWQX_PL9TN:5#- )(E)F=9^U57+98!EB%S'6&)D5^
M23ZS_"O6=$-$Q&3%F_"Z&"$5XHGGU$)I;7_"U$;D#"%#CS!<&]/^Q%C=_[&0
M6S-2V7B:>S:'L0O[H21?P((H7INPD("YD.+OP"4PAEN>D<*"RS9C,YI:?WK#
MN&27'JE8,4I!AT S*JWZY(MWJ&UCS^'V1Y,'=@(4K>40RZY15M23+07O46GM
M^1+AZ:D,SWNKE>X,+"<C_A00A_[GHPT'CX// "AZ6T/BC(V!ZP#>?MD(*2T^
M_ $9Q"47HJ')IJA(H>*-UA,*FKJ&$V#"D3^A:'U!<3'+0$8WX499(4H$C-#*
MYECQ,D*_T5:ZT==]U!\$$ZXYH='\^;33X6K%F(N*!\4T XBT<.1M_>Z)+VC6
MU(F')VX@;,7T?&Q<"^\<Y\C()N)8<#[OPD$Y(Z[_YX>X_NW#OMLFYLB</)/'
M1^DI7+6OH@-CW)E./Z.F?".7[/ERERQ%)/!L/\3M>F0N%KIG?U7*'H$"X8SL
MJ]S(W9<Q"=8R] U"PO _].V QLO^(CH%E"H=UF.ID$:TG&<9#K):B'_@H^0K
MJ,->X;7-*\[!5X0S"H.DD-5,.>J*)]>0L)'J";JT+$04@FM/6%I[K1 [$:([
M62,<?],GZ])[=$RO9]@>:,H8[QJ._M(< #6L9"##ZR=C<S^*G8%TD17%-^!X
M2(0S+X305RZTKF*IB556GD ]@B8Z"IJFZB29OLSQDW&<W+A!U4!"O-%N<AEE
MYO(9P$6"H?M&1,P)05^VPD<]D75W3;IP)P9'&&*Z2!L<G)("9E(PW9%WXNDU
M ]NBXQNT]Q43T;/UV;[4(TB55QR/%YO#RD#R?3]"*U?*+Y#H B&PY;2.P"DQ
M)HD7#O<V3[3LWD%6Y@4WST9'$22T((!3A[)KWK[#('RX\:+9^V[)G14'3??9
MYJF&01GFNK%S$4-<[@[LJ!P\U!7Z-H#?3IQB_3T;IX! JR/&=.STX=G Y*VZ
MOXVSS?\!/A5&$VU.?'GZ!UB#-,'R1(N>X]657& 13,/N-59@>9EB&P<<J>73
MIV0^SLQTH4#\$[#EID4ZS";1.$] (9 ^J:>JO# >=WV6C>DCR$3[&(NPW7/H
M-X,,)J, KURYU?2[#%AK.-@+#6<O^R"I!\F_H\I8E[5;XVC+ID5-4P\/:+ G
M5@WGWCE@17FAD-4E95ZH/CP;.2@,AU]5:+AC5AMCW-W1)HP+4$T826^RT,04
M'EU?F[NN@C4B>S#FJU'HQ<UZ%J[9H.*IDH \+ZLJ.J<@,UH0LF?C>8M-WSRX
MOA2W!X.^&L*AUKTPK=K;_;GW$>]/=Y8Y^G?__H#1.6_?<],Q?/2'[V15S+@0
M5W"BM5Z/IV8)F+?Q&I/;)FQLC"YG>+X85^\4>9#P%*PS1LK3@%LV)+,'3OCT
M,[_\O33-C2"A.L5&]<T=F9R44DH'[P,8@;GL^Q'.YJGH1RQ.-&I&_'R3 7"N
MI@^WFY[W,3?)G?3#CI,>MU2'$;5QON"!.L\4E%4=3)\CLI>+#UWN$E4T$0R8
MG=.<%NEI"2S*Z<"[L<W#S7 /2IBHOC'=RQ'.F1MF4/R&HQ$3B26@"CAWW/B
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M=Q#HRCAWW[).@E9!36:S6?BB459DH^F(+*8_\*^(:&WVS+T<ZN-.<BH.+.U
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MH>4W+Y+53)=^:W[:+3)LD!8SLVOTV%6?%L*!VE#\IA(SX?/TR'!&"9&9GR&
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M13#36&#5&2=/!EN_Q4F]-#:7?V.B8VA^F+@:F,_FX>"<F-<RH-_LLD9U#AD
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M2P$"% ,4    "  =B@91!E58KS\#  "5#   $0              @ $
M<V5L8BTR,#(P,#@P-BYX<V102P$"% ,4    "  =B@91A]18:_T*  #?AP
M%0              @ %N P  <V5L8BTR,#(P,#@P-E]L86(N>&UL4$L! A0#
M%     @ '8H&48Q7M8I6!P  .%D  !4              ( !G@X  '-E;&(M
M,C R,# X,#9?<')E+GAM;%!+ 0(4 Q0    ( !V*!E',Z.]8W!4   AN   2
M              "  2<6  !T;3(P,C8S-34M,U\X:RYH=&U02P$"% ,4
M"  =B@91S_&CUTNH   !H0, %0              @ $S+   =&TR,#(V,S4U
B9#-?97@Q+3$N:'1M4$L%!@     %  4 2 $  +'4      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
